

CITATION REPORT

List of articles citing

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

DOI: 10.1126/science.1129139
Science, 2006, 313, 1960-4.

Source: <https://exaly.com/paper-pdf/39640416/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2265	.		
2264	In Brief. 2006 , 6, 831-831		
2263	Interferons, immunity and cancer immunoediting. 2006 , 6, 836-48		1091
2262	In Reply. 2007 , 25, 463-464		2
2261	The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. 2007 , 56, 1572-8		38
2260	Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. 2007 , 25, 2586-93		836
2259	A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. 2007 , 12, 1084-95		121
2258	Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma. 2007 , 25, 2230-5		8
2257	Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis. 2007 , 82, 1-15		63
2256	Sensors of ionizing radiation effects on the immunological microenvironment of cancer. 2007 , 83, 819-25		88
2255	DNA microarray analysis: principles and clinical impact. 2007 , 12, 271-87		19
2254	Colorectal cancer: new advances in immunotherapy. 2007 , 6, 11-7		8
2253	Mucosally restricted antigens as novel immunological targets for antitumor therapy. 2007 , 1, 187-202		10
2252	Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. 2007 , 11, 235-44		21
2251	Cancer vaccines: a promising cancer therapy against all odds. 2007 , 3, 299-306		15
2250	Genetic modification of T cells for immunotherapy. 2007 , 7, 1167-82		7
2249	Association versus causation versus quality improvement: setting benchmarks for lymph node evaluation in colon cancer. 2007 , 99, 414-5		31

2248	Modulation of CD103 expression on human colon carcinoma-specific CTL. 2007 , 178, 2908-15	32
2247	Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. 2007 , 67, 10546-55	79
2246	Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model. 2007 , 67, 4800-6	18
2245	CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. 2007 , 104, 3967-72	354
2244	T-cell distribution and adhesion receptor expression in metastatic melanoma. 2007 , 13, 2549-56	59
2243	Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer. 2007 , 67, 11195-201	46
2242	Interleukin-12: biological properties and clinical application. 2007 , 13, 4677-85	454
2241	History of allergy and reduced incidence of colorectal cancer, Iowa Women's Health Study. 2007 , 16, 2357-62	40
2240	Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. 2007 , 179, 6686-95	12
2239	Dynamics of the immune reaction to pancreatic cancer from inception to invasion. 2007 , 67, 9518-27	668
2238	Is immunology more important than histopathology for colorectal cancer prognosis?. 2007 , 4, 4-5	
2237	Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. 2007 , 110, 2931-9	39
2236	Current World Literature. 2007 , 18, 289-307	
2235	Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. 2007 , 43, 624-31	51
2234	Loss of 1p36, gain of 8q24, and loss of 9q34 are associated with stroma percentage of colorectal cancer. 2007 , 258, 223-9	19
2233	Swords into plowshares: IL-23 repurposes tumor immune surveillance. 2007 , 28, 207-12	113
2232	Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. 2007 , 19, 203-8	232
2231	Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. 2007 , 9, R65	454

2230	Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. 2007 , 9, 212	475
2229	Tracking the elusive lymphocyte: methods of detection during adoptive immunotherapy. 2007 , 36, 807-27	1
2228	B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. 2007 , 67, 7893-900	198
2227	High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. 2007 , 67, 10669-76	167
2226	The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. 2007 , 67, 1883-6	298
2225	Le transcriptome comme outil d'analyse du stroma tumoral. 2007 , 27, 45-46	
2224	Tumor microenvironment and immune escape. 2007 , 16, 755-74, viii	75
2223	Current immunotherapeutic strategies in colon cancer. 2007 , 16, 873-900, x	10
2222	Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptor. 2007 , 5, 14	8
2221	Dendritic cell-based active specific immunotherapy for malignant glioma. 2007 , 7, 439-48	17
2220	The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. 2007 , 29, 387-98	138
2219	[The future of targeted therapeutics in oncology: targets to find, early and long term treatments]. 2007 , 23, 1073-4	0
2218	Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. 2007 , 48, 3223-9	27
2217	CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. 2007 , 121, 2013-22	37
2216	Immune cells as anti-cancer therapeutic targets and tools. 2007 , 101, 918-26	18
2215	Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. 2007 , 110, 2614-27	231
2214	Molecular profiling and risk stratification of adenocarcinoma of the colon. 2007 , 96, 693-703	37
2213	Does the immune reaction cause malignant transformation by disrupting cell-to-cell or cell-to-matrix communications?. 2007 , 4, 16	6

2212	Immunostimulation and immunoinhibition of premalignant lesions. 2007 , 4, 6	8
2211	50 & 100 Years Ago. 2007 , 450, 804-804	
2210	Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. 2007 , 82, 734-9	27
2209	Reply: Forkhead box P3-positive regulatory T cells in immune surveillance and cancer. 2007 , 97, 1017-1018	1
2208	Adaptive immunity maintains occult cancer in an equilibrium state. 2007 , 450, 903-7	999
2207	Cancer: immune pact with the enemy. 2007 , 450, 803-4	27
2206	Regulatory T cells and tumour immunity - observations in mice and men. 2008 , 123, 157-63	86
2205	The role of regulatory T cells in ovarian cancer. 2007 , 17, 764-70	13
2204	TAMEE: data management and analysis for tissue microarrays. 2007 , 8, 81	18
2203	Challenges and prospects of immunotherapy as cancer treatment. 2007 , 1776, 108-23	27
2202	Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. 2007 , 12, 898-910	119
2201	Mobilizing the low-avidity T cell repertoire to kill tumors. 2007 , 17, 317-29	41
2200	Do autochthonous tumors interfere with effector T cell responses?. 2007 , 17, 267-74	14
2199	Tumor immunoediting and immunosculpting pathways to cancer progression. 2007 , 17, 275-87	143
2198	Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. 2007 , 17, 459-68	44
2197	Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. 2007 , 189, 50-8	46
2196	Primary immune surveillance: some like it hot. 2007 , 85, 1361-7	11
2195	In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. 2007 , 56, 1539-49	19

2194	Tumor stromal barriers to the success of adoptive T cell therapy. 2008 , 57, 281-3	8
2193	Control of lymphocyte infiltration of lung tumors in mice by host's genes: mapping of four Lynf (lymphocyte infiltration) loci. 2008 , 57, 217-25	4
2192	Gene expression profiling reveals two separate mechanisms regulating apoptosis in rectal carcinomas in vivo. 2007 , 12, 1671-80	2
2191	Humoral immunity, inflammation and cancer. 2007 , 19, 209-16	319
2190	Image statistics and data mining of anal intraepithelial neoplasia. 2008 , 29, 2189-2196	10
2189	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. 2008 , 107, 249-57	140
2188	The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. 2008 , 57, 289-302	129
2187	Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. 2008 , 57, 813-21	107
2186	Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. 2008 , 57, 1635-45	30
2185	Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration. 2008 , 57, 1745-56	19
2184	Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?. 2008 , 57, 1531-9	24
2183	Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus. 2008 , 57, 1837-47	16
2182	Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. 2008 , 57, 1727-33	50
2181	Advances in immunotherapy for colorectal malignancies. 2008 , 4, 177-183	
2180	The follicular lymphoma microenvironment: From tumor cell to host immunity. 2008 , 3, 179-86	6
2179	Immunotherapy of colorectal cancer. 2008 , 1, 205-210	0
2178	Role of cancer microenvironment in metastasis: focus on colon cancer. 2008 , 1, 69-83	130
2177	Systems biology: a therapeutic target for tumor therapy. 2008 , 1, 159-70	52

2176	Genetic engineering of T cells for adoptive immunotherapy. 2008 , 42, 166-81	53
2175	Identification of patients with high-risk stage II colon cancer for adjuvant therapy. 2008 , 51, 503-7	176
2174	Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?. 2008 , 393, 995-1003	14
2173	Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. 2008 , 68, 1-10	55
2172	Systemic cancer therapy: evolution over the last 60 years. 2008 , 113, 1857-87	42
2171	EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. 2008 , 122, 342-9	39
2170	Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. 2008 , 123, 2120-9	72
2169	Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. 2008 , 123, 2605-15	24
2168	Inverse opal hydrogel-collagen composite scaffolds as a supportive microenvironment for immune cell migration. 2008 , 85, 815-28	88
2167	Role of Stat3 in suppressing anti-tumor immunity. 2008 , 20, 228-33	146
2166	Killer dendritic cells: IKDC and the others. 2008 , 20, 558-65	31
2165	The immune system--is it relevant to cancer development, progression and treatment?. 2008 , 20, 101-12	74
2164	Prognostic and predictive factors in colorectal cancer. 2008 , 61, 561-9	90
2163	Metinel node--the first lymph node draining a metastasis--contains tumor-reactive lymphocytes. 2008 , 15, 1454-63	13
2162	Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. 2008 , 15, 2310-7	40
2161	Cancer immunology. 2008 , 358, 2704-15	690
2160	Immune modulation by melanoma-derived factors. 2008 , 17, 977-85	59
2159	Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. 2008 , 222, 162-79	508

2158	Signaling defects in anti-tumor T cells. 2008 , 222, 192-205	78
2157	The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. 2008 , 222, 155-61	477
2156	The flip side of immune surveillance: immune dependency. 2008 , 222, 341-56	22
2155	The impact of T-cell immunity on ovarian cancer outcomes. 2008 , 222, 101-16	124
2154	Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma. 2008 , 60, 55-65	36
2153	Generalized maximally selected statistics. 2008 , 64, 1263-9	144
2152	Toll-like receptors and immune regulation: implications for cancer therapy. 2008 , 27, 181-9	122
2151	Polarized immune responses differentially regulate cancer development. 2008 , 222, 145-54	146
2150	Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. 2008 , 222, 287-98	70
2149	The Janus face of dendritic cells in cancer. 2008 , 27, 5920-31	72
2148	The tumor microenvironment and its role in promoting tumor growth. 2008 , 27, 5904-12	1343
2147	Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. 2008 , 27, 5913-9	89
2146	Immune escape as a fundamental trait of cancer: focus on IDO. 2008 , 27, 3889-900	260
2145	Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. 2008 , 98, 1886-93	83
2144	The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. 2008 , 99, 1013-9	58
2143	Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. 2008 , 99, 1712-7	32
2142	Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. 2008 , 99, 1704-11	211
2141	Opening the gateway to tumors. 2008 , 14, 13-4	2

2140	Vasopressin: friend or foe?. 2008 , 14, 14-6	11
2139	Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. 2008 , 14, 28-36	403
2138	DNA vaccines: precision tools for activating effective immunity against cancer. 2008 , 8, 108-20	341
2137	Immunological aspects of cancer chemotherapy. 2008 , 8, 59-73	1072
2136	T-cell death and cancer immune tolerance. 2008 , 15, 70-9	75
2135	Host response to colorectal cancer. 2008 , 78, 745-53	17
2134	Alteration of the immunological synapse in lung cancer: a microenvironmental approach. 2008 , 154, 48-55	13
2133	[Not Available]. 2008 , 145, 12S6-12S12	
2132	[Not Available]. 2008 , 145S4, 12S6-12S12	
2131	Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. 2008 , 9, 8	179
2130	[Immunosurveillance: a new prognostic factor in colorectal cancer]. 2008 , 32, 1098-100	
2129	Invariant natural killer T cells and immunotherapy of cancer. 2008 , 129, 182-94	29
2128	Macrophage polarization in tumour progression. 2008 , 18, 349-55	863
2127	Lymph node evaluation in early-stage colon cancer. 2008 , 7, 240-6	18
2126	Current state of vaccine therapies in non-small-cell lung cancer. 2008 , 9 Suppl 1, S28-36	21
2125	A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". 2008 , 6, 81	34
2124	Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. 2008 , 8, 561-72	69
2123	Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. 2008 , 135, 489-98	179

2122	Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. 2008 , 4, 137-49	64
2121	A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. 2008 , 10, R93	104
2120	Dendritic cell-based cancer vaccination: quo vadis?. 2008 , 7, 1041-53	19
2119	Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. 2008 , 14, 3254-61	314
2118	Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. 2008 , 39, 116-25	128
2117	The immunologic constant of rejection. 2008 , 29, 256-62	116
2116	Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat. 2008 , 26, 1764-72	11
2115	Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. <i>Science</i> , 2008 , 321, 974-7	333 802
2114	Prospects and challenges of building a cancer vaccine targeting telomerase. 2008 , 90, 173-80	40
2113	Cancer related inflammation: the macrophage connection. 2008 , 267, 204-15	425
2112	Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: prognostic value and effects of preoperative radio (chemo) therapy. 2008 , 44, 791-7	21
2111	Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. 2008 , 44, 1875-82	156
2110	Immune surveillance: a balance between protumor and antitumor immunity. 2008 , 18, 11-8	316
2109	Tumor-induced modulation of dendritic cell function. 2008 , 19, 65-77	79
2108	Telomerase as a universal tumor antigen for cancer vaccines. 2008 , 7, 881-7	48
2107	Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?. 2008 , 55, 147-67, xi	3
2106	Regulation of tumor immunity: the role of NKT cells. 2008 , 8, 725-34	25
2105	Targeted regulation of a lymphocyte-endothelial-interleukin-6 axis by thermal stress. 2008 , 24, 67-78	13

2104	Molecular classification and correlates in colorectal cancer. 2008 , 10, 13-27	318
2103	Macrophages define the invasive microenvironment in breast cancer. 2008 , 84, 623-30	313
2102	The essential role of the in situ immune reaction in human colorectal cancer. 2008 , 84, 981-7	84
2101	Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?. 2008 , 14, 5242-9	91
2100	Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. 2008 , 14, 5198-208	1044
2099	Crucial role of interleukin-4 in the survival of colon cancer stem cells. 2008 , 68, 4022-5	91
2098	CCR7 regulates B16 murine melanoma cell tumorigenesis in skin. 2008 , 84, 965-72	25
2097	Current status of prognostic immunohistochemical markers for urothelial bladder cancer. 2008 , 29, 311-22	22
2096	Spontaneous and treatment-induced cancer rejection in humans. 2008 , 8, 337-49	13
2095	Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. 2008 , 26, 4410-7	613
2094	Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. 2008 , 68, 2972-83	131
2093	A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. 2008 , 68, 34-43	39
2092	Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?. 2008 , 68, 9107-11	107
2091	Involvement of the leptin receptor in the immune response in intestinal cancer. 2008 , 68, 9413-22	35
2090	High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. 2008 , 57, 772-9	159
2089	High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. 2008 , 26, 2707-16	447
2088	Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. 2008 , 14, 2276-84	47
2087	Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]. 2008 , 14, 2111-8	112

2086	Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. 2008 , 68, 2436-46	38
2085	Capitalizing on the immunogenicity of dying tumor cells. 2008 , 14, 1603-8	44
2084	CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. 2008 , 14, 5626-34	59
2083	ANSWER. 2008 , 57, 779-779	
2082	Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. 2008 , 14, 1413-7	95
2081	Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients. 2008 , 14, 1073-9	20
2080	The anticancer immune response: indispensable for therapeutic success?. 2008 , 118, 1991-2001	450
2079	Inciting inflammation: the RAGE about tumor promotion. 2008 , 205, 267-70	39
2078	Patterns of cell signaling pathway activation that characterize mammary development. 2008 , 135, 2403-13	36
2077	Foxp3 and microsatellite stability phenotype in colorectal cancer. 2008 , 57, 725-6	7
2076	Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival. 2008 , 14, 1494-501	32
2075	Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. 2008 , 8, 1947-53	9
2074	IL-4-mediated drug resistance in colon cancer stem cells. 2008 , 7, 309-13	112
2073	Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. 2008 , 8, 385-95	17
2072	Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. 2008 , 205, 1687-700	96
2071	An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. 2008 , 31, 820-9	39
2070	Tumor immunology and immunotherapy. 2008 , 1181-1195	
2069	The role of signal transducers and activators of transcription in colon cancer. 2008 , 13, 2888-99	83

2068	Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. 2008 , 3, e3409	35
2067	Cocktails of human anti-cancer antibodies show a synergistic effect in nude mouse tumor xenografts. 2008 , 16, 87-98	2
2066	Epithelial Neoplasms of the Large Intestine. 2009 , 597-637	5
2065	BioBran-augmented maturation of human monocyte-derived dendritic cells. 2009 , 56, 89-95	29
2064	Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. 2009 , 4, e7234	26
2063	Estimation of immune cell densities in immune cell conglomerates: an approach for high-throughput quantification. 2009 , 4, e7847	25
2062	Neuroimmune mechanisms in postoperative ileus. 2009 , 58, 1300-11	221
2061	Immune gene and cell enrichment is associated with a good prognosis in ependymoma. 2009 , 183, 7428-40	45
2060	Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. 2009 , 106, 20429-34	257
2059	IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. 2009 , 182, 6951-8	74
2058	Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. 2009 , 101, 1513-21	74
2057	Mathematical Modelling of Tumour Dormancy. 2009 , 4, 68-96	5
2056	Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. 2009 , 15, 7642-7651	320
2055	Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. 2009 , 69, 6249-55	68
2054	Differences in tumor regulatory T-cell localization and activation status impact patient outcome. 2009 , 69, 7895-8	91
2053	In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. 2009 , 27, 5944-51	666
2052	Clinical states model for biomarkers in bladder cancer. 2009 , 5, 977-92	10
2051	Macroimmunology and immunotherapy of cancer. 2009 , 1, 367-83	4

2050	Dendritic-cell vaccination for prostate cancer. 2009 , 1, 63-72	1
2049	Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. 2009 , 17, 2049-57	45
2048	Tumorimmunologie und therapeutische immunologische Strategien in der Onkologie. 2009 , 41, 4-9	
2047	Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. 2009 , 16, 66-93	228
2046	Future of immunotherapy: a call for comparative immunology. 2009 , 1, 1-3	3
2045	The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC. 2009 , 24, 357-67	32
2044	Endothelin B receptor, a new target in cancer immune therapy. 2009 , 15, 4521-8	88
2043	Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging. 2009 , 234, 860-79	31
2042	Towards effective immunotherapy for lung cancer: simultaneous targeting of tumor-initiating cells and immune pathways in the tumor microenvironment. 2009 , 1, 721-5	6
2041	Genetic risk for colitis-associated colorectal cancer. 2009 , 58, 1177-9	2
2040	Role of hydrogen sulfide in visceral nociception. 2009 , 58, 744-7	23
2039	Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. 2009 , 15, 6412-20	291
2038	Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. 2009 , 15, 5878-87	158
2037	Regulation of NK cell function by human granulocyte arginase. 2009 , 182, 5259-67	80
2036	Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. 2009 , 69, 8420-8	53
2035	Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. 2009 , 183, 7752-60	42
2034	Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. 2009 , 10, 301	62
2033	Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. 2009 , 9, 184	45

2032	Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. 2009 , 114, 105-10	122
2031	IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. 2009 , 132, 71-82	39
2030	P.08 Valeur pronostique de l'instabilité microsatellitaire et de l'infiltration tumorale par des lymphocytes T mémoire, chez 137 cancers coliques opérés, de stade 2 et 3. 2009 , 33, A23	
2029	Common germline variation in mismatch repair genes and survival after a diagnosis of colorectal cancer. 2009 , 124, 1887-91	16
2028	HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers. 2009 , 125, 1231-7	27
2027	Regulatory T cells control macrophage accumulation and activation in lymphoma. 2010 , 127, 1131-40	21
2026	Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient. 2010 , 127, 1124-30	9
2025	Gadd45b and Gadd45g are important for anti-tumor immune responses. 2009 , 39, 3010-8	41
2024	Is lymph node count an ideal quality indicator for cancer care?. 2009 , 99, 265-8	35
2023	Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. 2009 , 135, 439-49	56
2022	DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis. 2009 , 135, 567-80	2
2021	Adoptive transfer of virus-specific and tumor-specific T cell immunity. 2009 , 21, 224-32	56
2020	Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. 2009 , 116, 69-77	85
2019	The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. 2009 , 13, 2011-8; discussion 2018-9	42
2018	Anaplastic lymphoma kinase: an oncogene for tumor vaccination. 2009 , 87, 669-77	7
2017	MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells. 2009 , 58, 135-44	9
2016	Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. 2009 , 58, 449-59	292
2015	TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. 2009 , 58, 801-8	40

2014	Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. 2009 , 58, 1545-56	26
2013	Lymph node harvest in colon cancer: influence of microsatellite instability and proximal tumor location. 2009 , 33, 2695-703	68
2012	Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. 2009 , 217, 21-31	88
2011	Immunotherapy for liver tumors: present status and future prospects. 2009 , 16, 30	19
2010	Cytokine gene-mediated immunotherapy: current status and future perspectives. 2009 , 100, 1389-96	48
2009	IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. 2009 , 10, 1314-9	312
2008	Does chemotherapy modify the immune surveillance of hematological malignancies?. 2009 , 23, 53-8	36
2007	Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. 2009 , 22, 373-84	30
2006	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. 2009 , 22, 393-402	196
2005	Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. 2009 , 22, 1186-95	115
2004	STATs in cancer inflammation and immunity: a leading role for STAT3. 2009 , 9, 798-809	2923
2003	Cancer micrometastases. 2009 , 6, 339-51	522
2002	CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. 2009 , 101, 1382-92	94
2001	T cell-mediated immunoregulation in the gastrointestinal tract. 2009 , 64, 505-19	64
2000	Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. 2009 , 74, 1-10	12
1999	The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. 2009 , 103, 399-405	69
1998	Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. 2009 , 1174, 107-17	10
1997	Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer. 2009 , 1174, 81-7	7

1996	T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. 2009 , 16, 2524-30	98
1995	Lymph node evaluation of colon cancer and its association with improved staging and survival in the Department of Defense Health Care System. 2009 , 16, 3080-6	16
1994	Coordination of intratumoral immune reaction and human colorectal cancer recurrence. 2009 , 69, 2685-93	200
1993	Modeling and simulation of the immune system as a self-regulating network. 2009 , 467, 79-109	35
1992	Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. 2009 , 106, 9809-14	101
1991	Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. 2009 , 69, 8412-9	77
1990	Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. 2009 , 106, 14010-5	43
1989	Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. 2009 , 50, 886-91	92
1988	Pharmaceutical Perspectives of Cancer Therapeutics. 2009 ,	11
1987	In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics. 2009 , 48, 231-8	6
1986	Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. 2009 , 45, 56-64	50
1985	Improving the efficacy of cancer immunotherapy. 2009 , 45, 1424-31	39
1984	The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. 2009 , 45, 1780-7	71
1983	Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. 2009 , 45, 1664-72	100
1982	Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. 2009 , 45, 2138-45	68
1981	The capacity of the immune system to control cancer. 2009 , 45, 2068-70	3
1980	Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer. 2009 , 35, 1268-72	17
1979	Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. 2009 , 279, 1-7	121

1978	Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. 2009 , 278, 9-16	50
1977	Skin immune surveillance by T cells--a new order?. 2009 , 21, 110-20	37
1976	Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. 2009 , 214, 441-53	140
1975	Cellular and molecular pathways linking inflammation and cancer. 2009 , 214, 761-77	210
1974	The effect of shark liver oil on the tumor infiltrating lymphocytes and cytokine pattern in mice. 2009 , 126, 565-70	12
1973	Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. 2009 , 50, 980-9	396
1972	Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. 2009 , 5, 379-90	57
1971	Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. 2009 , 137, 1270-9	229
1970	Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. 2009 , 15, 5898-906	87
1969	Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. 2009 , 7, 45	31
1968	Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report. 2009 , 7, 50	25
1967	Immune therapy for cancer. 2009 , 27, 83-117	476
1966	Dendritic Cells in Cancer. 2009 ,	1
1965	The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. 2009 , 100, 1061-7	73
1964	Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. 2009 , 58, 520-9	191
1963	Expression of chemokines and chemokine receptors in human colon cancer. 2009 , 460, 105-21	71
1962	The immune response to tumors. 2009 , Chapter 20, Unit 20.11	23
1961	Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. 2009 , 182, 7287-96	217

1960	Post-transplant immunotherapy: combining cancer vaccines with hematopoietic stem cell transplantation. 2009 , 8, 519-23	0
1959	Bispecific T-cell engaging antibodies for cancer therapy. 2009 , 69, 4941-4	424
1958	Chronic inflammation, the tumor microenvironment and carcinogenesis. 2009 , 8, 2005-13	183
1957	Critical role for CD8+FoxP3+ regulatory T cells in colon cancer immune response in humans. 2009 , 58, 743-4	13
1956	New frontiers in cell-based immunotherapy of cancer. 2009 , 19, 623-41	9
1955	Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. 2009 , 27, 186-92	752
1954	Immunotherapy in acute leukemia. 2009 , 46, 89-99	7
1953	CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. 2009 , 10, 877-84	183
1952	Lymphocyte infiltration and prognosis in colorectal cancer. 2009 , 10, 840-1	5
1951	Use of tumour-responsive T cells as cancer treatment. 2009 , 373, 673-83	127
1950	Adjuvant trials design in colon cancer. 2009 , 21, 367-8	
1949	Novel treatment of medullary thyroid cancer. 2009 , 16, 367-72	17
1948	Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. 2009 , 249, 788-93	122
1947	Clinical implications of microsatellite instability in sporadic colon cancers. 2009 , 21, 369-73	72
1946	Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator in colon cancer. 2009 , 144, 511-5	18
1945	Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. 2009 , 113, 1681-8	27
1944	Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. 2009 , 114, 1141-9	579
1943	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. 2009 , 114, 2149-58	162

1942	Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. 2009 , 114, 2936-44	118
1941	Double jeopardy. 2009 , 114, 1135-6	1
1940	Th17 cells in ovarian cancer. 2009 , 114, 1134-5	23
1939	Green Tea and Skin Cancer: Immunological Modulation and DNA Repair. 2009 , 471-499	
1938	New take on comparative immunology: relevance to immunotherapy. 2009 , 1, 355-66	6
1937	Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer. 2009 , 144, 835-40	11
1936	Tumor Systems Need to be Rendered Usable for a New Action-Theoretical Abstraction: The Starting Point for Novel Therapeutic Options. 2009 , 5, 232-242	21
1935	Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. 2009 , 32, 341-52	63
1934	Comparative-effectiveness research to standardize retrieved nodes for quality control in colorectal cancer. 2010 , 252, 202-3; author reply 203	1
1933	TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy. 2010 , 10, 374-80	34
1932	Antigen specificity determines the pro- or antitumoral nature of CD8+ T cells. 2010 , 184, 607-14	10
1931	AGE/RAGE axis in the development of abdominal aortic aneurysm. 2010 , 252, 203-5; author reply 205	3
1930	Comparative-Effectiveness Research to Standardize Retrieved Nodes for Quality Control in Colorectal Cancer. 2010 , 252, 203	
1929	HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy. 2010 , 33, 402-13	15
1928	Lichtenstein's Operation, Mesh Plug, or Prolene Hernia System Repair for Groin Hernia: Which is Better?. 2010 , 252, 199-200	
1927	Prognostication for Trunk and Retroperitoneal Sarcomas. 2010 , 252, 201-202	
1926	Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. 2010 , 33, 236-49	30
1925	Lichtenstein's operation, mesh plug, or prolene hernia system repair for groin hernia: which is better?. 2010 , 252, 199; author reply 199-200	6

1924	Prognostication for trunk and retroperitoneal sarcomas. 2010 , 252, 201; author reply 201-2	2
1923	AGE/RAGE Axis in the Development of Abdominal Aortic Aneurysm. 2010 , 252, 205	
1922	Don't Give Up on Bowel Preps yet. 2010 , 252, 200-201	
1921	. 2010 , 70, 1741-1741	
1920	Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. 2010 , 16, 399-403	211
1919	Don't give up on bowel preps-yet. 2010 , 252, 200; author reply 200-1	3
1918	Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25. 2010 , 37, 1439-52	6
1917	Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. 2010 , 115, 3520-30	399
1916	Capturing and characterizing immune cells from breast tumor microenvironment: an innovative surgical approach. 2010 , 17, 2677-84	11
1915	Loci controlling lymphocyte production of interferon γ after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility. 2010 , 59, 203-13	8
1914	Prognostic value of CD208-positive cell infiltration in gastric cancer. 2010 , 59, 389-95	24
1913	Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. 2010 , 59, 653-61	123
1912	Testing the theory of immune selection in cancers that break the rules of transplantation. 2010 , 59, 643-51	24
1911	Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. 2010 , 59, 909-19	49
1910	Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. 2010 , 59, 1163-71	121
1909	Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. 2010 , 59, 1197-209	125
1908	Phenotypic characterization of chronic inflammation in a rare case of endobronchial carcinoma. 2010 , 59, 1411-6	
1907	Pre-operative intracellular glutathione levels of peripheral monocytes as a biomarker to predict survival of colorectal cancer patients. 2010 , 59, 1457-65	3

1906	Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. 2010 , 59, 1401-9	71
1905	Early effects of low dose ion or X-ray irradiation on human peripheral blood lymphocytes. 2010 , 45, 832-838	6
1904	Morphometric analysis of the balance between CXCR3+ T cells and FOXP3+ regulatory T cells in lymphocyte-rich and conventional gastric cancers. 2010 , 456, 615-23	8
1903	Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. 2010 , 136, 1585-95	155
1902	Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. 2010 , 15, 544-51	37
1901	The tumor microenvironment in colorectal carcinogenesis. 2010 , 3, 149-66	137
1900	T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. 2010 , 3, 29-47	45
1899	PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer. 2010 , 46, 206-15	4
1898	How Might Knowledge of the Molecular Biology of Rectal Cancer Aid Us in Deciding Treatment?. 2010 , 6, 221-227	1
1897	Dysplasie des MICI: physiopathologie et point de vue du pathologiste. 2010 , 4, 199-205	
1896	TGFbeta and cancer metastasis: an inflammation link. 2010 , 29, 263-71	48
1895	Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy. 2010 , 128, 488-98	10
1894	Staging error does not explain the relationship between the number of lymph nodes in a colon cancer specimen and survival. 2010 , 147, 358-65	41
1893	Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction. 2010 , 11 Suppl 1, S7	15
1892	Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. 2010 , 11, 19	167
1891	The spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interaction. 2010 , 10, 179	12
1890	Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. 2010 , 10, 496	40
1889	High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. 2010 , 10, 608	41

1888	Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases. 2010 , 10, 82	29
1887	T regulatory cells, the evolution of targeted immunotherapy. 2010 , 1806, 7-17	19
1886	CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. 2010 , 18, 485-98	250
1885	The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. 2010 , 116, 222-33	28
1884	Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. 2010 , 116, 5188-99	84
1883	Bioluminescence imaging allows measuring CD8 T cell function in the liver. 2010 , 51, 1430-7	35
1882	Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. 2010 , 126, 2143-52	23
1881	High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. 2010 , 126, 2635-43	240
1880	NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. 2010 , 127, 381-93	41
1879	Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. 2010 , 127, 2300-12	58
1878	Immune evasion of microsatellite unstable colorectal cancers. 2010 , 127, 1001-10	105
1877	Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. 2010 , 40, 3325-35	99
1876	Cancer immunoediting and "spontaneous" tumor regression. 2010 , 206, 1-8	38
1875	Natural immunity to cancer in humans. 2010 , 22, 215-22	129
1874	Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. 2010 , 127, 77-84	93
1873	Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. 2010 , 222, 350-66	357
1872	T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases. 2010 , 12, 674-83	56
1871	The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. 2010 , 118, 371-82	35

1870	The biologic importance of tumor-infiltrating lymphocytes. 2010 , 37 Suppl 1, 48-53	31
1869	Cancer vaccines: Where are we going?. 2010 , 6 Suppl 1, S9-15	7
1868	Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules. 2010 , 161, 81-8	33
1867	Immunogenic death of colon cancer cells treated with oxaliplatin. 2010 , 29, 482-91	693
1866	Immune infiltration in human tumors: a prognostic factor that should not be ignored. 2010 , 29, 1093-102	725
1865	Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors. 2010 , 29, 1753-62	53
1864	Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. 2010 , 103, 685-92	35
1863	Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. 2010 , 11, 889-96	2436
1862	Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. 2010 , 10, 605-17	159
1861	T(H)17 cells in tumour immunity and immunotherapy. 2010 , 10, 248-56	460
1860	Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. 2010 , 1194, 169-78	50
1859	Perforin: structure, function, and role in human immunopathology. 2010 , 235, 35-54	136
1858	Liver transplantation for colorectal liver metastases: revisiting the concept. 2010 , 23, 679-85	55
1857	In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of Fungal Glycolipids. 2010 , 2, 773-93	9
1856	In vivo disruption of TGF-beta signaling by Smad7 in airway epithelium alleviates allergic asthma but aggravates lung carcinogenesis in mouse. 2010 , 5, e10149	23
1855	Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. 2010 , 5, e13474	58
1854	IFN- γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells. 2010 , 5, e14076	27
1853	TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. 2010 , 5, e14282	42

1852	Experimental metastasis and CTL adoptive transfer immunotherapy mouse model. 2010,	9
1851	A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. 2010, 15, 699-731	121
1850	Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. 2010, 16, 5824-34	52
1849	GDF-15 contributes to proliferation and immune escape of malignant gliomas. 2010, 16, 3851-9	105
1848	Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: the role of tenascin-C in immune suppression. 2010, 185, 1450-9	42
1847	Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. 2010, 28, 2881-8	64
1846	Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. 2010, 70, 9599-610	96
1845	Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. 2010, 70, 3515-25	50
1844	Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. 2010, 70, 2686-96	25
1843	Cancer and inflammation: promise for biologic therapy. 2010, 33, 335-51	254
1842	Correction. 2010, 59, 140-140	3
1841	Dual roles for immunity in gastrointestinal cancers. 2010, 28, 4045-51	154
1840	Epidermal gammadelta T cells sense precancerous cellular dysregulation and initiate immune responses. 2010, 22, 329-40	9
1839	Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. 2010, 70, 4829-39	52
1838	Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm. 2010, 28, e471-2; author reply e473	5
1837	Unravelling the complexity of cancer-immune system interplay. 2010, 10, 917-34	4
1836	Memory T Cells. 2010,	1
1835	Gene-expression profiling in vaccine therapy and immunotherapy for cancer. 2010, 9, 555-65	58

1834	Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy. 2010 , 28, e369-70; author reply e371	23
1833	Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. 2010 , 207, 1791-804	174
1832	Lung tumor development and spontaneous regression in lambs coinfectd with Jaagsiekte sheep retrovirus and ovine lentivirus. 2010 , 47, 148-62	18
1831	Quality assurance measures in rectal cancer: caveat utilitor. 2010 , 59, 139-40	4
1830	Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. 2010 , 107, 15187-92	20
1829	A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. 2010 , 70, 7476-88	109
1828	Investigational immunotherapeutics for B-cell malignancies. 2010 , 28, 884-92	21
1827	Immune signatures predict prognosis in localized cancer. 2010 , 28, 765-73	36
1826	IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. 2010 , 184, 2281-8	244
1825	Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. 2010 , 16, 4105-12	94
1824	Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. 2010 , 2010, 547179	102
1823	Vaccines against human carcinomas: strategies to improve antitumor immune responses. 2010 , 2010, 380697	35
1822	Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. 2010 , 2010, 690438	32
1821	Survival of MUTYH-associated polyposis patients with colorectal cancer and matched control colorectal cancer patients. 2010 , 102, 1724-30	35
1820	T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. 2010 , 185, 3174-83	118
1819	Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis. 2010 , 130, 1726-36	25
1818	Low density lipoprotein receptor mediates anti-VEGF effect of lymphocyte T-derived microparticles in Lewis lung carcinoma cells. 2010 , 10, 448-56	33
1817	In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. 2010 , 9, 2902-2907	5

1816	Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. 2010 , 70, 9538-43	24
1815	A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. 2010 , 70, 9041-52	36
1814	The role of inflammation in the pathogenesis of non-small cell lung cancer. 2010 , 5, 2024-36	187
1813	The crosstalk of RAS with the TGF- β family during carcinoma progression and its implications for targeted cancer therapy. 2010 , 10, 849-57	40
1812	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. 2010 , 23, 1104-12	162
1811	The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. 2010 , 17, 3449-61	40
1810	Anticancer properties of the IL-12 family--focus on colorectal cancer. 2010 , 17, 3303-8	39
1809	Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses. 2010 , 10, 735-48	8
1808	Subversion and coercion: the art of redirecting tumor immune surveillance. 2011 , 344, 25-39	3
1807	Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?. 2010 , 24, 109-27	1
1806	Monitoring immune responses after glioma vaccine immunotherapy. 2010 , 21, 195-9	4
1805	The origin and role of MHC class I-associated self-peptides. 2010 , 92, 41-60	11
1804	Immune responses to malignancies. 2010 , 125, S272-83	129
1803	New Trends in Cancer Therapy: Targeting Ion Channels and Transporters. 2010 , 3, 1202-1224	29
1802	The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. 2010 , 8, 112	105
1801	Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. 2010 , 8, 130	22
1800	Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients. 2010 , 8, 35	7
1799	Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice. 2010 , 8, 98	10

1798	Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. 2010 , 138, 1429-40	228
1797	Microsatellite instability in colorectal cancer. 2010 , 138, 2073-2087.e3	1249
1796	Inflammation and colon cancer. 2010 , 138, 2101-2114.e5	1323
1795	Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. 2010 , 139, 84-92.e2	125
1794	Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. 2010 , 138, 2197.e1-7	103
1793	Immune infiltration in human cancer: prognostic significance and disease control. 2011 , 344, 1-24	126
1792	Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. 2010 , 31, 37-49	468
1791	Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. 2010 , 41, 1758-69	50
1790	TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. 2010 , 31, 220-7	618
1789	CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. 2010 , 17, 1381-5	105
1788	Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. 2010 , 52, 370-9	183
1787	Visualizing cancer and immune cell function with metabolic positron emission tomography. 2010 , 20, 100-5	26
1786	Inflammation and oncogenesis: a vicious connection. 2010 , 20, 65-71	328
1785	Psychological factors in immunomodulation induced by cancer surgery: a review. 2010 , 85, 1-13	7
1784	Polymorphisms in cytokine genes and serum cytokine levels among New Mexican women with and without breast cancer. 2010 , 51, 18-24	26
1783	The chemokine system in cancer biology and therapy. 2010 , 21, 27-39	298
1782	Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates. 2010 , 34, 915-25	57
1781	Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. 2010 , 36, 670-7	50

1780	Immunity, inflammation, and cancer. 2010 , 140, 883-99	6783
1779	Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. 2010 , 109, 744-52	106
1778	Gene expression profiling and pathway analysis of superficial bladder cancer in rats. 2010 , 75, 742-9	10
1777	Whole tumor antigen vaccines. 2010 , 22, 132-43	147
1776	Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. 2010 , 22, 173-82	54
1775	Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. 2010 , 22, 144-54	37
1774	SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. 2010 , 28, 5794-802	25
1773	Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. 2010 , 24, 1118-23	66
1772	Tissue Microarrays. 2010 ,	1
1771	Immune regulation of cancer. 2010 , 28, 4531-8	318
1770	Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response. 2010 , 17, 718-23	39
1769	From Molecular to Modular Tumor Therapy. 2010 ,	5
1768	The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. 2011 , 105, 93-103	813
1767	Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. 2011 , 29, 1539-46	226
1766	The challenges of integrating molecular imaging into the optimization of cancer therapy. 2011 , 3, 603-31	12
1765	Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. 2011 , 71, 6997-7009	168
1764	Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. 2011 , 29, 610-8	692
1763	Bispecific antibodies engage T cells for antitumor immunotherapy. 2011 , 11, 843-53	66

1762	Thunder and lightning: immunotherapy and oncolytic viruses collide. 2011 , 19, 1008-16	179
1761	Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. 2011 , 236, 567-79	215
1760	Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. 2011 , 22, 702-9	88
1759	Transforming growth factor- β in the gastrointestinal and hepatic tumor microenvironment. 2011 , 141, 1167-78	141
1758	Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. 2011 , 3, 1235-51	39
1757	TH17 Cells in the Tumor Micro-environment. 2011 , 481-496	1
1756	Macrophages in cancer and infectious diseases: the 'good' and the 'bad'. 2011 , 3, 1185-202	22
1755	Insights into global mechanisms and disease by gene expression profiling. 2011 , 719, 269-98	2
1754	T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancer. 2011 , 30, 78	3
1753	Prognostic immune markers in non-small cell lung cancer. 2011 , 17, 5247-56	127
1752	Hiding the road signs that lead to tumor immunity. 2011 , 208, 1937-40	14
1751	Infiltraci3n linfocitaria en el c3ncer colorrectal. Valor pron3stico. 2011 , 10, 224-228	
1750	Sarcoma immunotherapy. 2011 , 3, 4139-50	3
1749	Cancer immunotherapy comes of age. 2011 , 480, 480-9	2374
1748	Systemic Therapy for Colon Cancer. 2011 , 167-183	
1747	Colorectal cancer vaccines in clinical trials. 2011 , 10, 899-921	23
1746	Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. 2011 , 179, 37-45	178
1745	Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. 2011 , 179, 436-51	36

1744	Development of novel targeted agents in the treatment of metastatic colorectal cancer. 2011 , 10, 266-78	5
1743	Autoantibodies in cancer: prognostic biomarkers and immune activation. 2011 , 8, 577-89	27
1742	Immune parameters affecting the efficacy of chemotherapeutic regimens. 2011 , 8, 151-60	490
1741	Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. 2011 , 216, 1192-202	69
1740	Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. 2011 , 72, 1022-8	33
1739	Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. 2011 , 167, 207-10	61
1738	Tumor-infiltrating lymphocytes contain a higher proportion of FOXP3(+) T lymphocytes in cervical cancer. 2011 , 110, 580-6	13
1737	Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. 2011 , 54, 497-505	194
1736	Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. 2011 , 29, 1949-55	961
1735	Prognostic and predictive impact of intra- and peritumoral immune infiltrates. 2011 , 71, 5601-5	297
1734	Harmonization of immune biomarker assays for clinical studies. 2011 , 3, 108ps44	81
1733	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. 2011 , 13, R126	261
1732	Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell. 2011 , 11, 383-9	5
1731	Critical Issues of Research on Circulating and Disseminated Tumor Cells in Cancer Patients. 486-500	
1730	The immune microenvironments of lung and intraocular tumors. 2011 , 98, 58-61	2
1729	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. 2011 , 2, 66	7
1728	The inflammatory microenvironment in colorectal neoplasia. 2011 , 6, e15366	119
1727	Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. 2011 , 6, e18801	156

1726	Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. 2011 , 6, e19495	148
1725	Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. 2011 , 6, e21418	35
1724	Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients. 2011 , 19, 239-45	6
1723	Multiple vaccinations: friend or foe. 2011 , 17, 379-96	12
1722	The impact of perioperative risk, tumor pathology and surgical complications on disease recurrence following potentially curative resection of colorectal cancer. 2011 , 254, 83-9	55
1721	Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. 2011 , 23, 787-93	61
1720	Therapeutic cancer vaccine development: will it ride the wave of new immunomodulatory agents?. 2011 , 17, 276	1
1719	Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. 2011 , 11, 734-51	81
1718	Hematopoietic derived cell infiltration of the intestinal tumor microenvironment in Apc Min/+ mice. 2011 , 17, 528-39	3
1717	Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. 2011 , 39, 1011-7	19
1716	IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. 2011 , 121, 3846-59	153
1715	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. 2011 , 9 Suppl 5, S1-32; quiz S33	195
1714	FOXP3 and survival in urinary bladder cancer. 2011 , 108, 1672-8	102
1713	Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma. 2011 , 102, 1522-31	40
1712	Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. 2011 , 102, 1972-6	8
1711	Low expression of Granzyme B in colorectal cancer is associated with signs of early metastatic invasion. 2011 , 59, 207-15	18
1710	Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. 2011 , 59, 482-95	25
1709	In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype. 2011 , 59, 965-74	16

1708	Immunological perspective of self versus tumor antigens: insights from the RIP-gp model. 2011 , 241, 164-79	16
1707	Colon cancer cells produce immunoregulatory glucocorticoids. 2011 , 30, 2411-9	63
1706	Cancer: Macrophages limit chemotherapy. 2011 , 472, 303-4	99
1705	Electronics: Power surfing on waves. 2011 , 472, 304-5	3
1704	50 & 100 years ago. 2011 , 472, 304-304	2
1703	Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. 2011 , 104, 1288-95	334
1702	Phenotypic characterization and functional analysis of human tumor immune infiltration after mechanical and enzymatic disaggregation. 2011 , 372, 119-26	21
1701	Chemokines in cancer related inflammation. 2011 , 317, 664-73	170
1700	Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. 2011 , 317, 1255-60	140
1699	In situ expression of the CCL20-CCR6 axis in lymphocyte-rich gastric cancer and its potential role in the formation of lymphoid stroma. 2011 , 61, 645-51	12
1698	Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. 2011 , 91, 1059-65; discussion 1065	39
1697	Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. 2011 , 19, 72-85	159
1696	IL-10 elicits IFN γ dependent tumor immune surveillance. 2011 , 20, 781-96	260
1695	The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. 2011 , 141, 338-47	55
1694	Natural innate and adaptive immunity to cancer. 2011 , 29, 235-71	1353
1693	Cancer immunology--analysis of host and tumor factors for personalized medicine. 2011 , 8, 711-9	209
1692	Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. 2011 , 7, 2997-3005	28
1691	Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. <i>Science</i> , 2011 , 331, 1565-70	333 3816

1690	CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. 2011 , 130, 645-55	214
1689	Tumor immunosurveillance in human cancers. 2011 , 30, 5-12	123
1688	Tumor microenvironment is multifaceted. 2011 , 30, 13-25	86
1687	Modulation of tumor immunity by therapeutic monoclonal antibodies. 2011 , 30, 111-24	21
1686	Microbial deprivation, inflammation and cancer. 2011 , 30, 211-23	21
1685	Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. 2011 , 26, 483-92	14
1684	Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges. 2011 , 60, 413-8	10
1683	Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. 2011 , 60, 433-42	103
1682	Suppression of T-cell responses by tumor metabolites. 2011 , 60, 425-31	67
1681	Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. 2011 , 60, 869-82	19
1680	B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. 2011 , 60, 1047-55	94
1679	Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?. 2011 , 60, 1153-60	52
1678	A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. 2011 , 60, 1739-50	33
1677	Prognostic impact of B-cell density in cutaneous melanoma. 2011 , 60, 1729-38	127
1676	Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. 2011 , 60, 1721-8	60
1675	Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. 2011 , 60, 1509-27	42
1674	Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. 2011 , 68, 1305-13	72
1673	The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. 2011 , 33, 335-40	82

1672	[WHO classification 2010 for the lower gastrointestinal tract: what is new?]. 2011 , 32 Suppl 2, 326-31	10
1671	Sub-chronic effect of perfluorooctanesulfonate (PFOS) on the balance of type 1 and type 2 cytokine in adult C57BL6 mice. 2011 , 85, 1235-44	69
1670	Tumour-infiltrating lymphocytes in cancer: implications for the diagnostic pathologist. 2011 , 17, 80-90	8
1669	T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. 2011 , 50, 269-75	54
1668	Lymphocytic host response to oral squamous cell carcinoma: an adaptive T-cell response at the tumor interface. 2011 , 5, 117-22	24
1667	Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. 2011 , 4, 141-54	242
1666	Cancer-immune equilibrium: questions unanswered. 2011 , 4, 209-17	25
1665	Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI. 2011 , 4, 377-92	69
1664	Variation in lymph node assessment after colon cancer resection: patient, surgeon, pathologist, or hospital?. 2011 , 15, 471-9	59
1663	A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. 2011 , 11, 419	22
1662	Protein kinase A antagonist inhibits β -catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/+) mice. 2011 , 10, 149	35
1661	An immunologic portrait of cancer. 2011 , 9, 146	77
1660	High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. 2011 , 9, 184	45
1659	Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". 2011 , 9, 32	25
1658	In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2. 2011 , 9, 33	22
1657	Induction of Th1Immune responses following laser ablation in a murine model of colorectal liver metastases. 2011 , 9, 83	8
1656	Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. 2011 , 6, 49	77
1655	Immunological network signatures of cancer progression and survival. 2011 , 4, 28	16

1654	Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. 2011 , 223, 347-57	97
1653	Reply to letter entitled "How dense, how intense? Role of tumour-infiltrating lymphocytes across colorectal cancer stages" Re: Noshu et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. <i>J Pathol</i> 2010; 222: 350B66. 2011 , 225, 629-630	
1652	Serum soluble vascular adhesion protein-1 is a valuable prognostic marker in gastric cancer. 2011 , 103, 695-9	19
1651	Modulation of human T-cell functions by reactive nitrogen species. 2011 , 41, 1843-9	50
1650	Cancer immunotherapy: Progress and challenges in the clinical setting. 2011 , 41, 1510-5	23
1649	Cancer: more of polygenic disease and less of multiple mutations? A quantitative viewpoint. 2011 , 117, 440-5	41
1648	Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. 2011 , 117, 5234-44	79
1647	Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. 2011 , 128, 2085-95	83
1646	Tumor infiltration by FcR111 (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. 2011 , 128, 2663-72	73
1645	Tumor-reactive CD4+ CD8 ^{hi} CD103+ β cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers. 2011 , 128, 2923-32	26
1644	Epidemiologic perspective on immune-surveillance in cancer. 2011 , 23, 265-71	60
1643	Immunosurveillance in human non-viral cancers. 2011 , 23, 272-8	37
1642	Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. 2011 , 17, 7440-50	68
1641	Is antigen specificity the key to efficient adoptive T-cell therapy?. 2011 , 3, 495-505	3
1640	The tumor microenvironment: part 1. 2011 , 3, 1367-84	18
1639	A novel adjuvant Ling Zhi-8 for cancer DNA vaccines. 2011 , 7, 1161-4	10
1638	Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. 2011 , 115, 505-11	81
1637	The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. 2011 , 7, 1223-35	74

1636	The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). 2011 , 18, 5217-23	58
1635	Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. 2011 , 24, 671-82	157
1634	Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. 2011 , 15, 579-88	15
1633	Type 1 and Type 2 cytokines imbalance in adult male C57BL/6 mice following a 7-day oral exposure to perfluorooctanesulfonate (PFOS). 2011 , 8, 30-8	42
1632	Targeting the tumor microenvironment by immunotherapy: part 2. 2011 , 3, 1385-408	5
1631	Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. 2011 , 17, 678-89	198
1630	Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. 2011 , 17, 1603-15	315
1629	CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. 2011 , 17, 4101-9	113
1628	Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. 2011 , 2, 240	211
1627	Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. 2011 , 186, 3462-71	87
1626	Lymphocyte infiltration in breast cancer: a key prognostic factor that should not be ignored. 2011 , 29, 1935-6	12
1625	Natural killer cells in human cancer: from biological functions to clinical applications. 2011 , 2011, 676198	134
1624	Conversion of tumors into autologous vaccines by intratumoral injection of β Gal glycolipids that induce anti-Gal/ β Gal epitope interaction. 2011 , 2011, 134020	8
1623	T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology. 2011 , 2011, 320571	12
1622	Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. 2011 , 2011, 174149	18
1621	Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. 2011 , 71, 1263-71	773
1620	IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. 2011 , 71, 5697-706	309
1619	Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. 2011 , 71, 5678-87	300

1618	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. 2011 , 17, 3064-76	87
1617	A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF- κ B in tumors. 2011 , 71, 3772-80	31
1616	Plasmacytoid dendritic cells and cancer. 2011 , 90, 681-90	64
1615	Gene Expression Profiling for In Silico Microdissection of Hodgkin's Lymphoma Microenvironment and Identification of Prognostic Features. 2011 , 2011, 4853-10	2
1614	Epigenetic quantification of tumor-infiltrating T-lymphocytes. 2011 , 6, 236-46	71
1613	Cytokines, inflammation and colon cancer. 2011 , 11, 451-64	197
1612	Early effects of low dose C ion or x-ray irradiation on peripheral blood lymphocytes of patients with alimentary tract cancer. 2011 , 9, 356-68	8
1611	Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. 2011 , 12, 357-66	8
1610	Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. 2011 , 25, 1510-27	276
1609	Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells. 2011 , 71, 4790-8	19
1608	Role of immune-regulatory cells in skin pathology. 2011 , 89, 41-9	9
1607	Controversies in clinical cancer dormancy. 2011 , 108, 12396-400	196
1606	CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer. 2011 , 12, 653-62	29
1605	Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. 2011 , 105, 1191-6	74
1604	T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. 2011 , 105, 366-71	47
1603	T-cell immune monitoring assays to guide the development of new cancer vaccines. 2011 , 156-166	
1602	Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. 2011 , 71, 5670-7	294
1601	TNM staging in colorectal cancer: T is for T cell and M is for memory. 2011 , 29, 601-3	72

1600	Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. 2011 , 71, 4809-20	239
1599	Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. 2011 , 3, 2904-54	10
1598	Novel immunotherapeutic strategies of gastric cancer treatment. 2011 , 2011, 437348	30
1597	A prospective evaluation of C-reactive protein levels and colorectal adenoma development. 2011 , 20, 537-44	28
1596	Colon Cancer Stem Cells: Bench-to-Bedside-New Therapeutical Approaches in Clinical Oncology for Disease Breakdown. 2011 , 3, 1957-74	9
1595	Cell surface markers in colorectal cancer prognosis. 2010 , 12, 78-113	41
1594	Prognostic value of colorectal cancer biomarkers. 2011 , 3, 2080-105	3
1593	The confluence of stereotactic ablative radiotherapy and tumor immunology. 2011 , 2011, 439752	114
1592	Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. 2011 , 71, 6143-52	82
1591	Regulatory T cells in colorectal cancer: from biology to prognostic relevance. 2011 , 3, 1708-31	14
1590	Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. 2011 , 208, 1949-62	455
1589	The role of tumour stroma in colorectal cancer invasion and metastasis. 2011 , 3, 2160-8	38
1588	Regulatory T cells in gastrointestinal tumors. 2011 , 5, 489-501	24
1587	TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. 2011 , 186, 1963-9	90
1586	Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. 2011 , 71, 736-46	97
1585	Heat shock proteins, autoimmunity, and cancer treatment. 2012 , 2012, 486069	54
1584	Modulation of immunity by antiangiogenic molecules in cancer. 2012 , 2012, 492920	81
1583	LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer. 2012 , 18, 5224-33	15

1582	The treg/th17 imbalance in patients with obstructive sleep apnoea syndrome. 2012 , 2012, 815308	27
1581	Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. 2012 , 9, e1001216	532
1580	The dual role of inflammation in colon carcinogenesis. 2012 , 13, 11071-84	67
1579	Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. 2012 , 2012, 741741	53
1578	Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time. 2012 , 19, 39-41	29
1577	Role of T lymphocytes in tumor response to radiotherapy. 2012 , 2, 95	112
1576	T cells in gastric cancer: friends or foes. 2012 , 2012, 690571	30
1575	The role of bacterial lipopolysaccharides as immune modulator in vaccine and drug development. 2012 , 12, 221-35	18
1574	Regulatory T cells in radiotherapeutic responses. 2012 , 2, 90	58
1573	Tertiary intratumor lymphoid tissue in colo-rectal cancer. 2011 , 4, 1-10	48
1572	The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytes. 2012 , 53, 598-604	14
1571	Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. 2012 , 23, 442-9	37
1570	The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. 2012 , 18, 3022-9	331
1569	Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. 2012 , 209, 2001-16	172
1568	For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. 2012 , 18, 2417-9	32
1567	Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. 2012 , 61, 427-38	234
1566	Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. 2012 , 72, 356-64	152
1565	Tumor-derived chemokine CCL5 enhances TGF- β -mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. 2012 , 72, 1092-102	144

1564	Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. 2012 , 4, 127ra37	1562
1563	Targeting ion channels in leukemias: a new challenge for treatment. 2012 , 19, 683-96	50
1562	Role of the microenvironment in the tumorigenesis of microsatellite unstable and MUTYH-associated polyposis colorectal cancers. 2012 , 27, 247-53	8
1561	Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. 2012 , 18, 2872-81	112
1560	Tumor-infiltrating B cells: The ignored players in tumor immunology. 2012 , 1, 1186-1188	46
1559	Immune system plays an important role in the success and failure of conventional cancer therapy. 2012 , 4, 125-8	12
1558	Sequential metastases of colorectal cancer: Immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments. 2012 , 1, 593-599	15
1557	Hunting for clues: Regulatory T cells and colorectal cancer. 2012 , 1, 1163-1164	
1556	Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. 2012 , 61, 1163-71	99
1555	Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. 2012 , 147, 366-72	108
1554	High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. 2012 , 1, 829-839	128
1553	The local immunological microenvironment in colorectal cancer as a prognostic factor for treatment decisions in the clinic: The way ahead. 2012 , 1, 62-66	6
1552	Trial watch: Chemotherapy with immunogenic cell death inducers. 2012 , 1, 179-188	86
1551	CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker?. 2012 , 1, 364-365	33
1550	Smoothing T cell roads to the tumor: Chemokine post-translational regulation. 2012 , 1, 390-392	5
1549	Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. 2012 , 1, 789-790	32
1548	B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. 2012 , 1, 1061-1073	33
1547	A model for cancer-suppressive inflammation. 2012 , 1, 1146-1155	54

1546	Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in tumors. 2012,	
1545	Liver immunology. 2012, 153-165.e2	
1544	Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. 2012, 2, 249	46
1543	Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation. 2012, 1, 298-305	14
1542	The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. 2012, 106, 2010-5	48
1541	Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. 2012, 31, 1242-53	37
1540	Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. 2012, 107, 1729-36	162
1539	Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. 2012, 18, 6284-95	44
1538	Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. 2012, 1, 1135-1145	44
1537	Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors. 2012, 189, 1920-7	57
1536	Survival prediction for patients with colorectal carcinoma incorporating tumor-infiltrating lymphocyte grade. 2012, 147, 371-2	
1535	NF- κ B hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. 2012, 72, 3735-43	97
1534	Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. 2012, 18, 3122-31	37
1533	Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases. 2012, 18, 1237-45	30
1532	Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. 2012, 3, 98	9
1531	Radiation as an immunological adjuvant: current evidence on dose and fractionation. 2012, 2, 153	214
1530	Trial Watch: Adoptive cell transfer immunotherapy. 2012, 1, 306-315	58
1529	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. 2012, 7, 267-72	11

1528	Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. 2012 , 28, 1131-8	83
1527	Immune cell infiltrate in different grades of astrocytomas. 2012 , 32, 175-180	2
1526	Th17 cells have stem cell-like features and promote long-term immunity. 2012 , 1, 516-519	39
1525	Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method. 2012 , 36, 202-13	29
1524	Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. 2012 , 35, 131-41	39
1523	Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. 2012 , 35, 418-29	38
1522	Cancer immunoediting in malignant glioma. 2012 , 71, 201-22; discussion 222-3	62
1521	Stem Cells and Colon Cancer. 2012 ,	
1520	Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. 2012 , 119, 2176-7	35
1519	CEBPE activation in PML-RARA cells by arsenic. 2012 , 119, 2177-9	8
1518	Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity. 2012 , 137, 226-38	10
1517	Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. 2012 , 14, e701-7	99
1516	Lignan constituents of <i>Tilia amurensis</i> and their biological evaluation on antitumor and anti-inflammatory activities. 2012 , 50, 3680-6	37
1515	The pros and cons of chemokines in tumor immunology. 2012 , 33, 496-504	80
1514	Blinatumomab: a historical perspective. 2012 , 136, 334-42	221
1513	Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients. 2012 , 135, 459-67	40
1512	Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. 2012 , 72, 1070-80	370
1511	Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. 2012 , 14, R39	59

1510	Surgical options for initially unresectable colorectal liver metastases. 2012 , 2012, 454026	19
1509	Bioinformatics for cancer immunology and immunotherapy. 2012 , 61, 1885-903	32
1508	FOXP3+ cell density in lymphoid follicles from histologically normal mucosa is a strong prognostic factor in early stage colon cancer. 2012 , 61, 1183-90	13
1507	CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. 2012 , 61, 1269-77	71
1506	Cancerous HLA class I expression and regulatory T cell infiltration in gastric cancer. 2012 , 61, 1663-9	14
1505	Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. 2012 , 61, 1849-56	93
1504	The roles of mast cells in anticancer immunity. 2012 , 61, 1511-20	56
1503	Mast cells impair the development of protective anti-tumor immunity. 2012 , 61, 2273-82	32
1502	Increased tumor-infiltrating CD8(+)Foxp3(+) T lymphocytes are associated with tumor progression in human gastric cancer. 2012 , 61, 2183-92	41
1501	Innate immune sensing of cancer: clues from an identified role for type I IFNs. 2012 , 61, 1343-7	39
1500	First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival. 2012 , 30, 875-7	14
1499	The outcome after stent placement or surgery as the initial treatment for obstructive primary tumor in patients with stage IV colon cancer. 2012 , 203, 715-9	39
1498	A new reliable bioassay for determining the biological activity of human interleukin-12 by using human NK cell line NKG cells. 2012 , 13, 109-13	3
1497	Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma. 2012 , 30, 680-7	12
1496	Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance. 2012 , 93, 315-8	3
1495	Therapeutic cancer vaccines: current status and moving forward. 2012 , 104, 599-613	207
1494	The adaptive immune response to colorectal cancer: from the laboratory to clinical practice. 2012 , 38, 889-96	12
1493	Roles of transforming growth factor- β in graft-versus-host and graft-versus-tumor effects. 2012 , 18, 1329-40	11

1492	Immune Surveillance Tissue Antigen Profiling in Advanced Ovarian Cancer. 2012 , 5, 78-86	1
1491	T cell subsets and colorectal cancer: discerning the good from the bad. 2012 , 279, 21-4	15
1490	Effector CD8+ T cell IFN- γ production and cytotoxicity are enhanced by mild hyperthermia. 2012 , 28, 9-18	59
1489	A novel chip-based parallel transfection assay to evaluate paracrine cell interactions. 2012 , 12, 1363-72	9
1488	Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. 2012 , 189, 767-76	23
1487	Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. 2012 , 29, 729-36	30
1486	Microsatellite instability testing in Korean patients with colorectal cancer. 2012 , 11, 459-66	31
1485	The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. 2012 , 19, 3581-90	47
1484	MSH3 protein expression and nodal status in MLH1-deficient colorectal cancers. 2012 , 18, 3142-53	17
1483	Recent approaches to identifying biomarkers for high-risk stage II colon cancer. 2012 , 42, 1037-45	24
1482	Host-derived MCP-1 and MIP-1 β regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. 2012 , 180, 365-74	45
1481	Can tissue-based immune markers be used for studying the natural history of cancer?. 2012 , 22, 520-30	11
1480	MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. 2012 , 56, 389-96	128
1479	Enhanced vascular permeability is hypothesized to promote inflammation-induced carcinogenesis and tumor development via extravasation of large molecular proteins into the tissue. 2012 , 78, 738-43	8
1478	The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. 2012 , 38, 451-66	121
1477	Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. 2012 , 491, 254-8	873
1476	NF- κ B directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. 2012 , 287, 25530-40	95
1475	The stable traits of melanoma genetics: an alternate approach to target discovery. 2012 , 13, 156	27

1474	Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. 2012 , 12, 134	60
1473	The clinical significance of tumor infiltrating lymphocytes in breast cancer: does subtype matter?. 2012 , 12, 135	4
1472	The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers. 2012 , 12, 418	22
1471	Profound tumor-specific Th2 bias in patients with malignant glioma. 2012 , 12, 561	14
1470	Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer. 2012 , 12, 24	16
1469	Cancer classification using the Immunoscore: a worldwide task force. 2012 , 10, 205	538
1468	Toward integrative cancer immunotherapy: targeting the tumor microenvironment. 2012 , 10, 70	36
1467	Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. 2012 , 10, 51	228
1466	Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. 2012 , 7, 156	22
1465	Anti-tumor immunity: myeloid leukocytes control the immune landscape. 2012 , 278, 21-6	18
1464	Image-Based Cell Quality Assessment: Modeling of Cell Morphology and Quality for Clinical Cell Therapy. 2012 , 207-226	5
1463	Colitis and colorectal cancer. 2012 , 30, 469-76	25
1462	Biomarkers and Personalized Medicine. 2012 , 327-353	
1461	The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. 2012 , 38, 943-55	39
1460	[Predictive value of intraepithelial (CD3) T-lymphocyte infiltration in resected colorectal cancer]. 2012 , 35, 541-50	
1459	Cancer immunotherapy. 2012 , 6, 242-50	69
1458	The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. 2012 , 6, 111-27	118
1457	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. 2012 , 1, 1323-1343	173

1456	Novel prognostic biomarkers in colorectal cancer. 2012 , 30, 296-303	5
1455	RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. 2012 , 8, 687-95	30
1454	Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. 2012 , 29, 1817-26	69
1453	Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. 2012 , 90, 869-71	3
1452	The immune contexture in human tumours: impact on clinical outcome. 2012 , 12, 298-306	2819
1451	Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. 2012 , 20, 1791-9	56
1450	Evasion of tumours from the control of the immune system: consequences of brief encounters. 2012 , 7, 31	35
1449	Accumulation of CCR4+CTLA-4 FOXP3+CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells. 2012 , 7, e30695	44
1448	Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. 2012 , 7, e32493	55
1447	Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. 2012 , 7, e38711	138
1446	Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. 2012 , 7, e42274	73
1445	Immune microenvironment in tumor progression: characteristics and challenges for therapy. 2012 , 2012, 608406	100
1444	Predictive immunological markers in oncology. 2011 , 2, 86	3
1443	Hypoxia promotes tumor growth in linking angiogenesis to immune escape. 2012 , 3, 21	114
1442	Lymph node harvest in colon and rectal cancer: Current considerations. 2012 , 4, 9-19	91
1441	Modulation of Tumor Angiogenesis by a Host Anti-Tumor Response in Colorectal Cancer. 2012 ,	
1440	Tumor Infiltrating Lymphocytes as Prognostic Factor of Early Recurrence and Poor Prognosis of Colorectal Cancer After Radical Surgical Treatment. 2012 ,	1
1439	Adaptive and Innate Immunity, Non Clonal Players in Colorectal Cancer Progression. 2012 ,	2

1438	Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens. 2012 , 32, 97-126	25
1437	The immune system: endogenous anticancer mechanism. 2012 , 4, 2354-64	4
1436	Impact of COX-2, IL-1 β , TNF- α , IL-4 and IL-10 on the process of carcinogenesis in the large bowel. 2012 , 63, 221-7	15
1435	B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. 2012 , 18, 971-8	39
1434	Extra-Adrenal Glucocorticoid Synthesis in Mucosal Tissues and Its Implication in Mucosal Immune Homeostasis and Tumor Development. 2012 ,	
1433	The immune score as a new possible approach for the classification of cancer. 2012 , 10, 1	455
1432	Tumor microenvironment and lymphocyte infiltration. 2012 , 61, 751-9	58
1431	Immune microenvironmental shift along human colorectal adenoma-carcinoma sequence: is it relevant to tumor development, biomarkers and biotherapeutic targets?. 2012 , 47, 367-77	19
1430	Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. 2012 , 188, 4441-9	69
1429	Cancer genomics: technology, discovery, and translation. 2012 , 30, 647-60	134
1428	Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. 2012 , 19, 217-24	380
1427	Multimodal treatment strategies for locally advanced rectal cancer. 2012 , 12, 481-94	8
1426	Targeting pattern recognition receptors in cancer immunotherapy. 2012 , 7, 29-54	100
1425	EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. 2012 , 14, 77-89	15
1424	Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. 2012 , 14, 428-39	71
1423	High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. 2012 , 106, 130-7	115
1422	Transcriptomic analysis of the woodchuck model of chronic hepatitis B. 2012 , 56, 820-30	76
1421	Shift from pStat6 to pStat3 predominance is associated with inflammatory bowel disease-associated dysplasia. 2012 , 18, 1267-74	14

1420	Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in murine tumors. 2012 , 130, 2618-28	30
1419	Serum MMP-8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. 2012 , 131, E463-74	46
1418	HLA-E/ β microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. 2012 , 131, 855-63	72
1417	Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF- β in breast cancer progression. 2012 , 131, 2584-95	53
1416	Antibody-based immunotherapy of cancer. 2012 , 148, 1081-4	186
1415	T-regulatory cells: key players in tumor immune escape and angiogenesis. 2012 , 72, 2162-71	509
1414	The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. 2012 , 72, 3557-69	64
1413	Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study. 2012 , 18, 509-18	4
1412	Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). 2012 , 5, 133-49	68
1411	Immunological effects of taxol and adryamicin in breast cancer patients. 2012 , 61, 481-8	24
1410	Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF- β activity. 2012 , 61, 701-11	21
1409	Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. 2012 , 61, 713-23	20
1408	Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. 2012 , 61, 771-82	31
1407	Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. 2012 , 61, 789-801	48
1406	Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape. 2012 , 61, 803-16	23
1405	CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice. 2012 , 61, 893-903	32
1404	Human ovarian cancer stem-like cells can be efficiently killed by γ T lymphocytes. 2012 , 61, 979-89	33
1403	An immune-active tumor microenvironment favors clinical response to ipilimumab. 2012 , 61, 1019-31	562

1402	Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. 2012 , 61, 1045-53	31
1401	Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity. 2012 , 61, 1055-64	
1400	Reflections upon human cancer immune responsiveness to T cell-based therapy. 2012 , 61, 761-70	10
1399	Harmonization of the intracellular cytokine staining assay. 2012 , 61, 967-78	39
1398	An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. 2012 , 460, 455-65	70
1397	The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?. 2012 , 138, 723-8	17
1396	Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. 2012 , 133, 881-8	78
1395	Colorectal cancer mouse models: integrating inflammation and the stroma. 2012 , 27, 39-50	18
1394	Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. 2012 , 167, 188-94	21
1393	Experimental mouse tumour models: what can be learnt about human cancer immunology?. 2011 , 12, 61-6	85
1392	CD95 signaling in colorectal cancer. 2012 , 1826, 189-98	10
1391	The many faces of Janus kinase. 2012 , 83, 1136-45	95
1390	Immunoediting the cancer genome--a new approach for personalized cancer therapy?. 2012 , 25, 297-8	4
1389	Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses. 2012 , 22, 50-9	26
1388	What are regulatory T cells (Treg) regulating in cancer and why?. 2012 , 22, 327-34	206
1387	Spatiotemporal effects of a possible chemorepulsion of tumor cells by immune system effectors. 2012 , 296, 41-8	6
1386	Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma. 2012 , 125, 186-93	18
1385	Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. 2012 , 168, 186-91	31

1384	Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. 2012 , 12, 5	25
1383	Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. 2012 , 19, 1944-53	63
1382	Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. 2012 , 42, 89-100	93
1381	Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer. 2012 , 122, 121-7	98
1380	Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. 2012 , 99, 287-94	69
1379	Impact de la réponse immunitaire dans le cancer du côlon: des perspectives encourageantes. 2012 , 6, 1-2	1
1378	Immunotherapy with MVA-BN β -HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. 2012 , 61, 19-29	16
1377	Microsatellite instability, EMAST, and morphology associations with T cell infiltration in colorectal neoplasia. 2012 , 57, 72-8	37
1376	Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinical outcomes of gastric cancer. 2013 , 11, 153	25
1375	Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". 2013 , 11, 137	18
1374	Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. 2013 , 11, 70	23
1373	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. 2013 , 11, 54	91
1372	Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results. 2013 , 32, 6	32
1371	Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. 2013 , 14, R34	131
1370	B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. 2013 , 111, 257-64	74
1369	Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. 2013 , 109, 131-7	60
1368	Therapeutic cancer vaccines: past, present, and future. 2013 , 119, 421-75	361
1367	The immune microenvironment of human tumors: general significance and clinical impact. 2013 , 6, 117-22	93

1366	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. 2013 , 13, 190	7
1365	Gene expression profiles in canine mammary carcinomas of various grades of malignancy. 2013 , 9, 78	11
1364	Digital pattern recognition-based image analysis quantifies immune infiltrates in distinct tissue regions of colorectal cancer and identifies a metastatic phenotype. 2013 , 109, 1618-24	28
1363	Head and neck squamous carcinomas with exophytic and endophytic type of growth have the same prognosis after surgery and adjuvant radiotherapy. 2013 , 270, 1105-14	6
1362	The clinical implication of tumoral Gal-1 expression in laryngeal squamous cell carcinomas. 2013 , 15, 608-18	1
1361	High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. 2013 , 352, 351-9	50
1360	Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery?. 2013 , 27, 731-41	36
1359	Effector CD4 and CD8 T cells and their role in the tumor microenvironment. 2013 , 6, 123-33	190
1358	Local immune response predicts survival in patients with thick (t4) melanomas. 2013 , 20, 3610-7	14
1357	Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. 2013 , 133, 1643-52	39
1356	The speed of change: towards a discontinuity theory of immunity?. 2013 , 13, 764-9	101
1355	Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells. 2013 , 14, 1330-7	47
1354	Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. 2013 , 62, 1575-85	44
1353	A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. 2013 , 62, 1327-34	1
1352	Anti-metastatic potential of human V α 1(+) T cells in an orthotopic mouse xenograft model of colon carcinoma. 2013 , 62, 1199-210	28
1351	Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. 2013 , 62, 553-61	67
1350	Chimeric adenoviral vector Ad5F35L containing the Ad5 natural long-shaft exhibits efficient gene transfer into human T lymphocytes. 2013 , 194, 52-9	5
1349	Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines. 2013 , 29, 431-7	26

1348	Deciphering and reversing tumor immune suppression. 2013 , 39, 61-73	392
1347	Facteurs pronostiques des cancers colorectaux localisés. 2013 , 7, 134-142	2
1346	Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. 2013 , 145, 1121-32	310
1345	Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. 2013 , 39, 611-21	294
1344	Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. 2013 , 39, 782-95	1595
1343	A "big data" view of the tumor "immunome". 2013 , 39, 631-2	15
1342	Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. 2013 , 20, 946-55	106
1341	The Association Between Inflammation and Colorectal Cancer. 2013 , 67-105	1
1340	Cell and Molecular Biology of Breast Cancer. 2013 ,	8
1339	Epigenetics and colorectal cancer pathogenesis. 2013 , 5, 676-713	159
1338	Digital genomic quantification of tumor-infiltrating lymphocytes. 2013 , 5, 214ra169	44
1337	Tumor-associated immune parameters for personalized patient care. 2013 , 5, 214fs42	4
1336	Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer. 2013 , 73, 629-39	59
1335	Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. 2013 , 63, 225-33	90
1334	Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. 2013 , 19, 4951-60	134
1333	Decreased expression of interleukin-36 β correlates with poor prognosis in hepatocellular carcinoma. 2013 , 62, 1675-85	26
1332	The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. 2013 , 13, 436	49
1331	Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. 2013 , 13, 422	49

1330	Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells. 2013 , 13, 592	14
1329	Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer. 2013 , 30, 727	14
1328	Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature. 2013 , 30, 698	18
1327	Prognostic value of Th17 cells in acute leukemia. 2013 , 30, 732	17
1326	Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. 2013 , 142, 355-64	20
1325	Innate and adaptive immune cells in the tumor microenvironment. 2013 , 14, 1014-22	2160
1324	Advances in the development of cancer immunotherapies. 2013 , 34, 90-8	34
1323	Cancer immunotherapy: current status and future directions. 2013 , 22, 765-83	18
1322	From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. 2013 , 25, 261-7	325
1321	Systems Biology of Tumor Dormancy. 2013 ,	6
1320	Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. 2013 , 734, 91-107	26
1319	Detailed analysis of inflammatory cell infiltration in colorectal cancer. 2013 , 109, 1839-47	98
1318	Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?. 2013 , 11, 141-8	38
1317	The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. 2013 , 39, 11-26	554
1316	Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. 2013 , 39, 74-88	609
1315	Cancer Immunoediting. 2013 , 85-99	3
1314	Immunosurveillance. 2013 , 101-113	2
1313	Th17 Cells in Cancer. 2013 , 129-147	

1312	Immune Escape. 2013 , 149-164	1
1311	The Association of Immune Cell Infiltration and Prognosis in Colorectal Cancer. 2013 , 9, 372-379	10
1310	Review article: antitumoural immunity in colorectal cancer - current and potential future implications in clinical practice. 2013 , 38, 3-15	9
1309	Characterization of the melanoma brain metastatic niche in mice and humans. 2013 , 2, 155-63	23
1308	Common pathways to tumor rejection. 2013 , 1284, 75-9	14
1307	Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome. 2013 , 6, 387-401	15
1306	Ensemble learning of colorectal cancer survival rates. 2013 ,	2
1305	Unsuspected allies: chemotherapy teams up with immunity to fight cancer. 2013 , 43, 2538-42	6
1304	Autoantibodies and Biomarker Discovery. 2013 , 363-378	1
1303	Immune classification of colorectal cancer patients: impressive but how complete?. 2013 , 13, 517-26	16
1302	Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor α (IL-12R α), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. 2013 , 31, 490-8	141
1301	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. 2013 , 73, 1733-41	564
1300	Dendritic cell immunotherapy in ovarian cancer. 2013 , 13, 43-53	7
1299	Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. 2013 , 49, 1673-82	30
1298	Phenotypic characterisation of immune cell infiltrates in testicular germ cell neoplasia. 2013 , 100, 135-45	27
1297	CCL18 as an independent favorable prognostic biomarker in patients with colorectal cancer. 2013 , 183, 163-9	26
1296	Cancer immunotherapy: accomplishments to date and future promise. 2013 , 4, 1307-20	70
1295	Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. 2013 , 29, 464-73	25

1294	Noncanonical roles of the immune system in eliciting oncogene addiction. 2013 , 25, 246-58	10
1293	IFN- β -driven intratumoral microenvironment exhibits superior prognostic effect compared with an IFN- β -driven microenvironment in patients with colon carcinoma. 2013 , 183, 1897-1909	13
1292	Metastatic melanoma in the older patient: special considerations. 2013 , 31, 311-6	9
1291	CD33+/p-STAT1+ double-positive cell as a prognostic factor for stage IIIa gastric cancer. 2013 , 30, 442	21
1290	Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. 2013 , 19, 2598-604	43
1289	Combining radiotherapy and cancer immunotherapy: a paradigm shift. 2013 , 105, 256-65	685
1288	Suppression, subversion and escape: the role of regulatory T cells in cancer progression. 2013 , 171, 36-45	147
1287	Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?. 2013 , 6, 173-6	6
1286	New targets for the immunotherapy of colon cancer-does reactive disease hold the answer?. 2013 , 20, 157-68	16
1285	High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. 2013 , 44, 1630-7	23
1284	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. 2013 , 25, 268-76	275
1283	Vaccines against advanced melanoma. 2013 , 31, 179-90	18
1282	NMR-Based Metabolomics. 2013 , 311-392	5
1281	Molecular pathways and cellular metabolism in colorectal cancer. 2013 , 30, 12-25	43
1280	High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma. 2013 , 139, 1295-302	20
1279	Antibody-based therapy in colorectal cancer. 2013 , 5, 533-45	21
1278	The history of Lynch syndrome. 2013 , 12, 145-57	58
1277	Sporadische Tumoren des Kolorektums. 2013 , 611-661	

1276	Polyphenols from the bark of <i>Rhus verniciflua</i> and their biological evaluation on antitumor and anti-inflammatory activities. 2013 , 92, 113-21	63
1275	Novel drug discovery opportunities for colorectal cancer. 2013 , 8, 1153-64	17
1274	Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?. 2013 , 40, 347-60	13
1273	Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer. 2013 , 5, 870-876	34
1272	Towards a vaccine to prevent cancer in Lynch syndrome patients. 2013 , 12, 307-12	42
1271	Cell Death Signaling in Cancer Biology and Treatment. 2013 ,	1
1270	The Tumor Immunoenvironment. 2013 ,	3
1269	Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. 2013 , 49, 2233-42	319
1268	T cell-based gene therapy of cancer. 2013 , 161, 365-79	16
1267	The gastrointestinal tumor microenvironment. 2013 , 145, 63-78	105
1266	Tumour heterogeneity and immune-modulation. 2013 , 13, 497-503	27
1265	Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer?. 2013 , 39, 89-96	69
1264	Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. 2013 , 109, 1013-22	38
1263	CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. 2013 , 104, 1237-44	78
1262	Esophageal carcinosarcoma: a unique entity with better prognosis. 2013 , 20, 997-1004	28
1261	Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. 2013 , 20, 697-702	43
1260	The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma. 2013 , 63, 852-61	33
1259	Characterization of the inflammatory response to solid cancer metastases in the human brain. 2013 , 30, 69-81	62

1258	Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. 2013 , 109, 2705-13	207
1257	High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin E-producing dendritic cells in human breast cancer. 2013 , 191, 2001-8	93
1256	Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. 2013 , 62, 529-39	19
1255	T-cell receptor repertoires of tumor-infiltrating lymphocytes after hyperthermia using functionalized magnetite nanoparticles. 2013 , 8, 891-902	17
1254	Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. 2013 , 132, 1971-6	59
1253	Influence of human immune cells on cancer: studies at the University of Colorado. 2013 , 55, 22-33	11
1252	The invisible arm of immunity in common cancer chemoprevention agents. 2013 , 6, 764-73	31
1251	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. 2013 , 12, 597-615	49
1250	[Immune response and colorectal cancer]. 2013 , 100, 283-94	9
1249	Mobilizing and evaluating anticancer T cells: pitfalls and solutions. 2013 , 12, 1325-40	4
1248	Immune aspects of the breast tumor microenvironment. 2013 , 2, 231-244	11
1247	[Immunotherapy for colorectal cancer]. 2013 , 100, 871-85	3
1246	Home sweet home: the tumor microenvironment as a haven for regulatory T cells. 2013 , 4, 197	58
1245	Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues. 2013 , 4, 241	32
1244	The tumor microenvironment: a pitch for multiple players. 2013 , 3, 90	102
1243	Immune responses to cancer: are they potential biomarkers of prognosis?. 2013 , 3, 107	62
1242	Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. 2013 , 3, 231	102
1241	Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. 2013 , 3, 63	66

1240	Therapeutic dendritic cell-based cancer vaccines: the state of the art. 2013 , 33, 489-547	34
1239	Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. 2013 , 50, 239-44	20
1238	Immune infiltrates as predictive markers of survival in pancreatic cancer patients. 2013 , 4, 210	67
1237	The role of the immune response in merkel cell carcinoma. 2013 , 5, 234-54	28
1236	The role of chronic inflammation in obesity-associated cancers. 2013 , 2013, 697521	70
1235	The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. 2013 , 86, 20130281	28
1234	How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. 2013 , 4, 292	34
1233	Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. 2013 , 2013, 713859	38
1232	Prediction of response to anticancer immunotherapy using gene signatures. 2013 , 31, 2369-71	40
1231	Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs. 2013 , 36, 258-67	21
1230	Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. 2013 , 36, 224-31	91
1229	VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. 2013 , 73, 539-49	397
1228	Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. 2013 , 36, 477-89	174
1227	A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. 2013 , 258, 879-86	97
1226	Victories and deceptions in tumor immunology: Stimuvax. 2013 , 2, e23687	38
1225	Colorectal carcinoma infiltration by myeloperoxidase-expressing neutrophil granulocytes is associated with favorable prognosis. 2013 , 2, e25990	14
1224	Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer. 2013 , 32, 269-76	7
1223	IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. 2013 , 73, 4653-62	98

1222	Role of T17 cytokines in the control of colorectal cancer. 2013 , 2, e26617	69
1221	Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration. 2013 , 2, e24116	33
1220	The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. 2013 , 2, e23618	21
1219	A constructed HLA-A2-restricted pMAGE-A1(278-286) tetramer detects specific cytotoxic T lymphocytes in tumour tissues in situ. 2013 , 41, 1811-24	4
1218	The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. 2013 , 8, 1226-35	16
1217	MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. 2013 , 6, 18-26	166
1216	A novel probe for the non-invasive detection of tumor-associated inflammation. 2013 , 2, e23034	80
1215	Molecular Profiling of Immunotherapeutic Resistance. 2013 , 373-394	2
1214	Expression of leukotriene B ₄ receptor-1 on CD8+ T cells is required for their migration into tumors to elicit effective antitumor immunity. 2013 , 191, 3462-70	32
1213	GBP-1 acts as a tumor suppressor in colorectal cancer cells. 2013 , 34, 153-62	63
1212	Evolution Theory: Its Practical Relevance for Understanding Tumor Development and Specifying Tumor Therapy. 2013 , 191-238	
1211	Pleiotropic and Differential Functions of IL-1 α and IL-1 β Shape the Tumor Microenvironment and Affect the Outcome of Malignancies. 2013 , 197-222	
1210	Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. 2013 , 1, 99-111	37
1209	Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival. 2013 , 10, 35-47	101
1208	Tumor-infiltrating mast cells in colorectal cancer as a poor prognostic factor. 2013 , 21, 111-20	17
1207	Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis. 2013 , 45, 371-81	16
1206	TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. 2013 , 4, 363	64
1205	Tumor-altered dendritic cell function: implications for anti-tumor immunity. 2013 , 4, 192	74

1204	Progressive Increase of Regulatory T Cells and Decrease of CD8+ T Cells and CD8+ T Cells/Regulatory T Cells Ratio during Colorectal Cancer Development. 2013 , 47, 443-51	27
1203	Peripheral helper lymphocytes produce interleukin 12 in cancer patients. 2013 , 7, 75-81	5
1202	Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?. 2013 , 26, 167-75	9
1201	Immune cells: plastic players along colorectal cancer progression. 2013 , 17, 1088-95	53
1200	Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients. 2013 , 132, 1842-50	30
1199	Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. 2013 , 140, 1-11	152
1198	Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches. 2013 , 133, 2145-56	22
1197	Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer. 2013 , 104, 531-5	23
1196	Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. 2013 , 19, 4079-91	213
1195	Immunosurveillance against tetraploidization-induced colon tumorigenesis. 2013 , 12, 473-9	28
1194	In situ conversion of tumors into autologous tumor-associated antigen vaccines by intratumoral injection of α -gal glycolipids. 2013 , 2, e22449	5
1193	Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics. 2013 , 19, 765-778	28
1192	Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. 2013 , 191, 2217-25	78
1191	Regulatory T cells, leptin and angiogenesis. 2014 , 99, 155-69	20
1190	Biological Niches Characterizing Pathological Lesions. 2013 , 5, 139-173	1
1189	The role of soluble CD40L in immunosuppression. 2013 , 2, e22546	18
1188	Tremelimumab: a review of development to date in solid tumors. 2013 , 5, 215-29	44
1187	[Targeted therapy: old and new possibilities]. 2013 , 36 Suppl 5, 2-11	1

1186	Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. 2013 , 109, 2665-74	145
1185	The in situ local immune response, tumour senescence and proliferation in colorectal cancer. 2013 , 109, 2207-16	19
1184	Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. 2013 , 109, 1031-9	35
1183	Prognostic value of peritumoral heat-shock factor-1 in patients receiving resection of hepatocellular carcinoma. 2013 , 109, 1648-56	15
1182	IRF-1 responsiveness to IFN- β predicts different cancer immune phenotypes. 2013 , 109, 76-82	42
1181	The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. 2013 , 109, 1676-84	91
1180	Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. 2013 , 19, 5626-35	293
1179	Escalating regulation of 5T4-specific IFN- γ CD4 T cells distinguishes colorectal cancer patients from healthy controls and provides a target for therapy. 2013 , 1,	14
1178	Reg3 β deficiency impairs pancreatic tumor growth by skewing macrophage polarization. 2013 , 73, 5682-94	45
1177	Role of dendritic cells in the regulation of antitumor immunity. 2013 , 2, e23973	11
1176	STAT3 activation: A key factor in tumor immunoescape. 2013 , 2, e23010	113
1175	The two faces of regulatory T cells in cancer. 2013 , 2, e23852	9
1174	Clinical impact of tumor-infiltrating CD45RO+ memory T cells on human gastric cancer. 2013 , 29, 1756-62	36
1173	Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. 2013 , 11, 242	36
1172	[At the crossroads of cancer]. 2013 , 100, 569-74	3
1171	Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. 2013 , 56, 142-9	64
1170	RNase-L deficiency exacerbates experimental colitis and colitis-associated cancer. 2013 , 19, 1295-305	19
1169	Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. 2013 , 11, 145	64

1168	A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. 2013 , 4, 2288-301	34
1167	Lymph node ratio predicts tumor recurrence in stage III colon cancer. 2013 , 40, 463-70	6
1166	Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma. 2013 , 8, e47434	32
1165	Th inducing POZ-Kruppel Factor (ThPOK) is a key regulator of the immune response since the early steps of colorectal carcinogenesis. 2013 , 8, e54488	8
1164	Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. 2013 , 8, e57114	183
1163	B cells promote tumor progression via STAT3 regulated-angiogenesis. 2013 , 8, e64159	82
1162	B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. 2013 , 8, e76012	116
1161	Chemotherapy sensitizes colon cancer initiating cells to VβVα T cell-mediated cytotoxicity. 2013 , 8, e65145	35
1160	Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. 2013 , 4, 236	25
1159	New insights into the role of the immune microenvironment in breast carcinoma. 2013 , 2013, 785317	45
1158	Sizing up a slow assault on cancer. 2013 , 496, 14-5	4
1157	Role of IL-17 in Glioma Progression. 2013 , Suppl 1,	12
1156	Pancreatic carcinoma development: new etiological and pathogenetic evidence. 2013 , 7, 242	1
1155	Therapeutic cancer vaccines and combination immunotherapies involving vaccination. 2014 , 3, 135-50	8
1154	Role of Rip2 in development of tumor-infiltrating MDSCs and bladder cancer metastasis. 2014 , 9, e94793	12
1153	Decreased expression of GATA2 promoted proliferation, migration and invasion of HepG2 in vitro and correlated with poor prognosis of hepatocellular carcinoma. 2014 , 9, e87505	21
1152	Intratumoral CD8+ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. 2014 , 9, e95475	44
1151	B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. 2014 , 9, e99008	60

1150	Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. 2014 , 9, e100461	56
1149	Deconvolution of the gene expression profiles of valuable banked blood specimens for studying the prognostic values of altered peripheral immune cell proportions in cancer patients. 2014 , 9, e100934	5
1148	Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers. 2014 , 9, e111757	22
1147	High frequency of CD8 positive lymphocyte infiltration correlates with lack of lymph node involvement in early rectal cancer. 2014 , 2014, 792183	10
1146	Macrophages, Neutrophils, and Cancer: A Double Edged Sword. 2014 , 2014, 1-14	28
1145	Interleukin-17 and type 17 helper T cells in cancer management and research. 2014 , 3, 39-54	16
1144	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. 2014 , 5, 165	99
1143	PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. 2014 , 7, 1349-59	32
1142	Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance. 2014 , 20, 3719-37	45
1141	Colorectal cancer and immunity: what we know and perspectives. 2014 , 20, 3738-50	93
1140	Prognostic stratification of colorectal cancer patients: current perspectives. 2014 , 6, 291-300	36
1139	Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. 2014 , 7, 1071-81	24
1138	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. 2014 , 3, 151-65	9
1137	A clinical perspective on the role of chronic inflammation in gastrointestinal cancer. 2014 , 7, 261-72	20
1136	The Utility of Pro-inflammatory Cytokines-TNF Alpha and CRP as Indicators of Response to Chemotherapy in Patients with Breast Carcinoma. 2014 , 05,	0
1135	Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. 2014 , 124, 1810-20	224
1134	Controversies in Adjuvant Chemotherapy. 2014 , 177-199	1
1133	Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. 2014 , 20, 6774-85	63

1132	Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. 2014 , 5, 4651-64	70
1131	. 2014 ,	4
1130	The preoperative lymphocyte to monocyte ratio predicts clinical outcomes in patients with stage II/III gastric cancer. 2014 , 35, 11659-66	52
1129	Consensus guidelines for the detection of immunogenic cell death. 2014 , 3, e955691	524
1128	Cancer colorectal : compte rendu anatomopathologique type en 2014. 2014 , 16, 525-536	1
1127	slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells. 2014 , 5, 3029	31
1126	Developing T cell cancer immunotherapy in the dog with lymphoma. 2014 , 55, 169-81	11
1125	The immune landscape of human tumors: Implications for cancer immunotherapy. 2014 , 3, e27456	75
1124	Accuracy of TNM staging in colorectal cancer: a review of current culprits, the modern role of morphology and stepping-stones for improvements in the molecular era. 2014 , 49, 1153-63	39
1123	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. 2014 , 12, 291	28
1122	Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. 2014 , 96, 449-57	85
1121	Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. 2014 , 3, e27884	61
1120	Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. 2014 , 10, 477-486	
1119	Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. 2014 , 7, 91	18
1118	Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine. 2014 , 10, 2312-20	3
1117	Characterization of an adaptive immune response in microsatellite-unstable colorectal cancer. 2014 , 3, e29256	60
1116	Immune mediators as potential diagnostic tools for colorectal cancer: from experimental rationale to early clinical evidence. 2014 , 14, 387-99	6
1115	Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. 2014 , 110, 489-500	229

1114	Overcoming tumor-mediated immunosuppression. 2014 , 6, 973-88	28
1113	Clinicopathological analysis of CD8-positive lymphocytes in the tumor parenchyma and stroma of hepatocellular carcinoma. 2014 , 8, 2284-2290	8
1112	Does the immune system naturally protect against cancer?. 2014 , 5, 197	141
1111	Control of the immune response by pro-angiogenic factors. 2014 , 4, 70	187
1110	Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers. 2014 , 6, 969-97	40
1109	CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. 2014 , 142, 452-8	71
1108	Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3 ⁺ T cells exhibit more potent immunosuppressive activity than Foxp3 ⁺ regulatory T cells. 2014 , 7, 428-39	91
1107	Tobacco exposure by various modes may alter proinflammatory (IL-12) and anti-inflammatory (IL-10) levels and affects the survival of prostate carcinoma patients: an explorative study in North Indian population. 2014 , 2014, 158530	13
1106	Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. 2014 , 2014, 639058	18
1105	Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis. 2014 , 2014, 686879	63
1104	Collaborative Care in NSCLC; the Role of Early Palliative Care. 2014 , 4, 192	7
1103	Orchestration of angiogenesis by immune cells. 2014 , 4, 131	74
1102	Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C. 2014 , 2014, 462958	5
1101	Histological Analysis of T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. 2014 , 5, 632	15
1100	The tumor border configuration of colorectal cancer as a histomorphological prognostic indicator. 2014 , 4, 29	35
1099	T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept. 2014 , 8, 486	15
1098	A role for T-lymphocytes in human breast cancer and in canine mammary tumors. 2014 , 2014, 130894	47
1097	Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. 2014 , 5, 191	50

1096	Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response. 2014 , 13, 1814-27	31
1095	Sipuleucel-T and immunotherapy in the treatment of prostate cancer. 2014 , 14, 709-19	8
1094	Trafficking of T cells into tumors. 2014 , 74, 7168-74	225
1093	Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. 2014 , 20, 2147-58	168
1092	Reprogramming tumor-infiltrating dendritic cells for CD103+ CD8+ mucosal T-cell differentiation and breast cancer rejection. 2014 , 2, 487-500	51
1091	Advances in Tumor Immunology and Immunotherapy. 2014 ,	0
1090	Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours. 2014 , 134, 530-41	27
1089	Nano-Oncologicals. 2014 ,	4
1088	Application of central immunologic concepts to cancer: helping T cells and B cells become intolerant of tumors. 2014 , 44, 1921-4	6
1087	The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. 2014 , 110, 2551-9	79
1086	Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. 2014 , 44, 994-1004	18
1085	Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. 2014 , 14, 524-9	22
1084	The use of endogenous T cells for adoptive transfer. 2014 , 257, 250-63	49
1083	Identification of genes expressed by immune cells of the colon that are regulated by colorectal cancer-associated variants. 2014 , 134, 2330-41	28
1082	PD-1 blockade induces responses by inhibiting adaptive immune resistance. 2014 , 515, 568-71	4014
1081	Why is melanoma so metastatic?. 2014 , 27, 19-36	69
1080	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. 2014 , 25, 1536-43	433
1079	T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. 2014 , 134, 563-74	31

1078	The immunological synapse. 2014 , 2, 1023-33	203
1077	Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist. 2014 , 2, 1163-74	11
1076	Epithelial ovarian cancer - more data, more questions?. 2014 , 164, 479-86	11
1075	Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. 2014 , 257, 83-90	190
1074	Prognosis according to histochemical analysis of liver metastases removed at liver resection. 2014 , 101, 1681-91	43
1073	BRAF-targeted therapy alters the functions of intratumoral CD4 T cells to inhibit melanoma progression. 2014 , 3, e29126	4
1072	IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model. 2014 , 2, 1103-12	13
1071	T cells but not NK cells are associated with a favourable outcome for resected colorectal liver metastases. 2014 , 14, 180	17
1070	The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. 2014 , 1, 396-412	50
1069	A Phase I/II study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon- β and interleukin-2 in patients with renal cell carcinoma. 2014 , 37, 237-44	20
1068	Intraperitoneal oxidative stress in rabbits with papillomavirus-associated head and neck cancer induces tumoricidal immune response that is adoptively transferable. 2014 , 20, 4289-301	13
1067	Analysis of CD8+ and CD4+ cells in oral squamous cell carcinoma and their association with lymph node metastasis and histologic grade of malignancy. 2014 , 22, 200-5	7
1066	TGF- β in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression. 2014 , 37, 63-72	29
1065	Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. 2014 , 6, 228ra37	141
1064	The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer. 2014 , 3, e967142	5
1063	The immune microenvironment: a major player in human cancers. 2014 , 164, 13-26	49
1062	Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 T-cell response, prominent infiltration of CD8 lymphocytes and Th1 type polarization. 2014 , 3, e958937	28
1061	Therapeutic Efficacy and Systemic Antitumor T Cell Immunity Induced by RheoSwitch-Regulated IL-12 Expression after Intratumoral Injection of Adenovirus Vector or Vector-Transduced Dendritic Cells. 2014 , 363-376	4

1060	Perspectives on reprogramming cancer-associated dendritic cells for anti-tumor therapies. 2014 , 4, 72	13
1059	Machine Learning in Medical Imaging. 2014 ,	5
1058	Differences in TCR-V β repertoire and effector phenotype between tumor infiltrating lymphocytes and peripheral blood lymphocytes increase with age. 2014 , 9, e102327	10
1057	The role of complement in tumor growth. 2014 , 772, 229-62	124
1056	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. 2014 , 37-51	
1055	Evaluating biomarkers in melanoma. 2014 , 4, 383	33
1054	The impact of the immune system on tumor: angiogenesis and vascular remodeling. 2014 , 4, 69	105
1053	Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer. 2014 , 2, 15	1
1052	Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. 2014 , 74, 705-15	306
1051	Cancer immunoprevention: a new approach to intercept cancer early. 2014 , 7, 1067-71	18
1050	TGF β inhibition prior to hypofractionated radiation enhances efficacy in preclinical models. 2014 , 2, 1011-22	40
1049	High proportions of CD4+ T cells among residual bone marrow T cells in childhood acute lymphoblastic leukemia are associated with favorable early responses. 2014 , 131, 28-36	10
1048	Functional and genetic studies of isolated cells from parathyroid tumors reveal the complex pathogenesis of parathyroid neoplasia. 2014 , 111, 3092-7	41
1047	Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. 2014 , 111, 5896-901	72
1046	Microbiota and immune responses in colon cancer: more to learn. 2014 , 20, 232-6	9
1045	Disruption of the thymic microenvironment is associated with thymic involution of transitional cell cancer. 2014 , 92, 104-15	5
1044	The interplay between HPV and host immunity in head and neck squamous cell carcinoma. 2014 , 134, 2755-63	82
1043	The immune network in pancreatic cancer development and progression. 2014 , 33, 2956-67	136

1042	Virus infection, inflammation and prevention of cancer. 2014 , 193, 33-58	10
1041	Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer. 2014 , 142, 195-204	7
1040	Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. 2014 , 143, 1-9	21
1039	Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. 2014 , 63, 59-65	47
1038	Comparison of visual and automated assessment of tumour inflammatory infiltrates in patients with colorectal cancer. 2014 , 50, 544-52	13
1037	Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses. 2014 , 12, 210-20	5
1036	CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. 2014 , 21 Suppl 3, S414-21	92
1035	Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma. 2014 , 14, 64	19
1034	Tumor infiltrating B-cells are increased in prostate cancer tissue. 2014 , 12, 30	108
1033	Prognostic biomarkers in colorectal cancer: where do we stand?. 2014 , 464, 379-91	27
1032	Immune-epithelial crosstalk at the intestinal surface. 2014 , 49, 375-87	48
1031	3D cell culture systems modeling tumor growth determinants in cancer target discovery. 2014 , 69-70, 29-41	312
1030	Immunotherapy for solid tumors--a review for surgeons. 2014 , 187, 525-35	14
1029	The immune contexture of primary and metastatic human tumours. 2014 , 27, 8-15	85
1028	The clinical utility of the local inflammatory response in colorectal cancer. 2014 , 50, 309-19	69
1027	Complement anaphylatoxins as immune regulators in cancer. 2014 , 3, 747-58	37
1026	Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. 2014 , 74, 2710-8	29
1025	T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. 2014 , 4, 522-6	246

1024	Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. 2014 , 20, 607-15	524
1023	An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. 2014 , 58, 282-91	12
1022	GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer. 2014 , 20, 3094-106	45
1021	Antitumor effects of sulfated polysaccharides produced from marine algae. 2014 , 4, 122-132	7
1020	"In vitro" 3D models of tumor-immune system interaction. 2014 , 79-80, 145-54	63
1019	IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. 2014 , 40, 772-784	238
1018	Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. 2014 , 13, 117-30	30
1017	Interaction of Immune and Cancer Cells. 2014 ,	
1016	Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. 2014 , 19, 493-505	11
1015	Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. 2014 , 40, 205-14	62
1014	CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. 2014 , 20, 44-55	185
1013	Colorectal cancer. 2014 , 383, 1490-1502	1879
1012	Clinical evaluation of systemic and local immune responses in cancer: time for integration. 2014 , 63, 45-57	48
1011	In vivo discovery of immunotherapy targets in the tumour microenvironment. 2014 , 506, 52-7	159
1010	Cancer. Can cancer trigger autoimmunity?. <i>Science</i> , 2014 , 343, 147-8	333 8
1009	Tumor microenvironment and cellular stress: signaling, metabolism, imaging, and therapeutic targets. Preface. 2014 , 772, v-viii	22
1008	Roles of tumor suppressors in regulating tumor-associated inflammation. 2014 , 21, 1677-86	39
1007	Recognition of tumors by the innate immune system and natural killer cells. 2014 , 122, 91-128	233

1006	The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. 2014 , 148, 467-76	158
1005	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. 2014 , 3, e22	48
1004	STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. 2014 , 41, 830-42	876
1003	Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. 2014 , 32, 2959-66	780
1002	Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance. 2014 , 6, 1191-204	62
1001	Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. 2014 , 110, 459-68	115
1000	The Role of Predictive Molecular Biomarkers for the Treatment of Metastatic Colorectal Cancer. 2014 , 10, 395-402	3
999	High endothelial venule-like vessels and lymphocyte recruitment in testicular seminoma. 2014 , 2, 282-9	15
998	Tumoral presence of human cytomegalovirus is associated with shorter disease-free survival in elderly patients with colorectal cancer and higher levels of intratumoral interleukin-17. 2014 , 20, 664-71	20
997	Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. 2014 , 110, 2560-8	191
996	Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle. 2014 , 1846, 560-75	31
995	Mechanism of action of immunotherapy. 2014 , 41 Suppl 5, S3-13	89
994	Considerations for combined immune checkpoint modulation and radiation treatment. 2014 , 182, 230-8	7
993	The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. 2014 , 182, 170-81	70
992	The path to reactivation of antitumor immunity and checkpoint immunotherapy. 2014 , 2, 926-36	22
991	Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. 2014 , 147, 1393-404	380
990	Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies. 2014 , 83, 237-46	36
989	Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. 2014 , 189, 832-44	340

988	PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. 2014 , 111, 1391-9	68
987	Acquired and intrinsic resistance in cancer immunotherapy. 2014 , 8, 1132-9	133
986	Tracking cellular and immune therapies in cancer. 2014 , 124, 257-96	24
985	Prognostic and predictive values of the immunoscore in patients with rectal cancer. 2014 , 20, 1891-9	230
984	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. 2014 , 14, 768-74	191
983	Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells. 2014 , 354, 407-16	29
982	Leveling cancer with IL-15. 2014 , 7, 449-449	
981	Polarized immune responses modulated by layered double hydroxides nanoparticle conjugated with CpG. 2014 , 35, 9508-16	55
980	STAT of the union: dynamics of distinct tumor-associated macrophage subsets governed by STAT1. 2014 , 44, 2238-42	13
979	Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8. 2014 , 154, 116-26	32
978	High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. 2014 , 74, 2204-16	27
977	Inflammatory biomarkers and bladder cancer prognosis: a systematic review. 2014 , 66, 1078-91	66
976	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. 2014 , 14, 1219-28	1
975	WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. 2014 , 74, 2510-9	56
974	Molecular insights into the development of T cell-based immunotherapy for prostate cancer. 2014 , 10, 1547-57	6
973	Shaping of an effective immune microenvironment to and by cancer cells. 2014 , 63, 991-7	25
972	Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. 2014 , 21, 3142-50	80
971	Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells. 2014 , 134, 2841-52	6

970	Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. 2014 , 232, 199-209	882
969	Adoptive immunotherapy for cancer. 2014 , 257, 14-38	100
968	TGF-beta in CAF-mediated tumor growth and metastasis. 2014 , 25, 15-22	209
967	Identification of antitumor lignans from the seeds of morning glory (<i>Pharbitis nil</i>). 2014 , 62, 7746-52	18
966	Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development. 2014 , 28, 421-37	15
965	Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. 2014 , 14, 297	33
964	CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. 2014 , 13, 34	23
963	CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. 2014 , 12, 81	41
962	MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPilimumab. 2014 , 12, P11	8
961	Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. 2014 , 110, 1595-605	203
960	Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. 2014 , 20, 5995-6005	112
959	Cancer-related inflammation and treatment effectiveness. 2014 , 15, e493-503	945
958	Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma. 2014 , 24, 1232-40	15
957	Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases. 2014 , 2, 530-7	32
956	Characteristics and significance of colorectal cancer associated lymphoid reaction. 2014 , 134, 2126-35	75
955	Commentary--Digging deeper into tumor invasion as a prognostic factor for oral squamous cell carcinoma. 2014 , 72, 415-8	1
954	Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer. 2014 , 50, 457-67	14
953	Can calcium signaling be harnessed for cancer immunotherapy?. 2014 , 1843, 2334-40	6

952	FoxP3 demethylation is increased in human colorectal cancer and rat cholangiocarcinoma tissue. 2014 , 47, 201-5	7
951	Heterogeneity in immune responses: from populations to single cells. 2014 , 35, 219-29	117
950	Linking T-cell receptor sequence to functional phenotype at the single-cell level. 2014 , 32, 684-92	339
949	Molecular Mechanisms of Angiogenesis. 2014 ,	3
948	Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. 2014 , 74, 4258-69	68
947	Cell-death-associated molecular patterns as determinants of cancer immunogenicity. 2014 , 20, 1098-116	31
946	[Immunology and personalized medicine in oncology]. 2014 , 101 Suppl 1, S12-7	1
945	Cutpoint Methods in Digital Pathology and Companion Diagnostics. 2014 , 359-371	1
944	Immunoscore: a new possible approach for melanoma classification. 2014 , 2,	7
943	Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. 2014 , 123, 1412-21	59
942	Potential of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. 2014 , 1, 14004	28
941	General Malignancy after Organ Transplantation. 2014 , 1134-1146	
940	Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors. 2014 , 32, 2753-9	15
939	[Intratumoral immune microenvironment and survival: the immunoscore]. 2014 , 30, 439-44	15
938	Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery. 2014 , 24, 1319-25	53
937	Reprogramming immune responses via microRNA modulation. 2013 , 1,	3
936	Strong T-cell costimulation can reactivate tumor antigen-specific T cells in late-stage metastasized colorectal carcinoma patients: results from a phase I clinical study. 2015 , 46, 71-7	11
935	Nanomedicines Targeting the Tumor Microenvironment. 2015 , 21, 314-21	53

934	Gene therapy: progress and predictions. 2015 , 282, 20143003	88
933	The prognostic influence of tumor infiltrating Foxp3(+)CD4(+), CD4(+) and CD8(+) T cells in resected non-small cell lung cancer. 2015 , 12, 63	30
932	The role of magnetic resonance imaging-T2* in the evaluation of iron overload early in hereditary hemochromatosis. A cross-sectional study with 159 patients. 2015 , 90, E220-1	7
931	Mouse models of colorectal cancer as preclinical models. 2015 , 37, 909-20	48
930	Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor. 2015 , 10, 1301-1310	33
929	Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis. 2015 , 37, 1560-71	146
928	Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. 2015 , 5, 15659	93
927	Principles of Targeted Immunotherapy. 2015 , 27-38	
926	Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. 2015 , 126, 2882-91	52
925	The status of donor cancer tissues affects the fate of patient-derived colorectal cancer xenografts in NOG mice. 2015 , 64, 181-90	4
924	On the Verge: Immunotherapy for Colorectal Carcinoma. 2015 , 13, 970-8	9
923	Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. 2015 , 125, 739-51	96
922	Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. 2015 , 5, 15179	488
921	Principles of immunotherapy. 2015 , 13, 670-2	6
920	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. 2015 , 9, 35-43	4
919	CD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer. 2015 , 17, 839-48	46
918	Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model. 2015 , 5, 47	1
917	An der Schwelle zu einem neuen Zeitalter. 2015 , 18, 96-97	

916	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. 2015 , 13, 217	30
915	Loss of tapasin correlates with diminished CD8(+) T-cell immunity and prognosis in colorectal cancer. 2015 , 13, 279	24
914	Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. 2015 , 3, 47	85
913	Metabolic plasticity of human T cells: Preserved cytokine production under glucose deprivation or mitochondrial restriction, but 2-deoxy-glucose affects effector functions. 2015 , 45, 2504-16	54
912	Quantitative contribution of prognosticators to oncologic outcome after rectal cancer resection. 2015 , 58, 566-74	7
911	Palliative Cancer Patients' Experiences of Participating in a Lifestyle Intervention Study While Receiving Chemotherapy. 2015 , 38, E52-8	9
910	The Ruesch Center Symposium 2014: Fighting a Smarter War against Cancer Using Immunotherapy. 2015 , 4, 63-68	
909	The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer. 2015 , 15, 717	19
908	The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. 2015 , 15, 783	33
907	A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial). 2015 , 15, 988	10
906	Preoperative neutrophil-to-lymphocyte ratio predicts recurrence of patients with single-nodule small hepatocellular carcinoma following curative resection: a retrospective report. 2015 , 13, 265	21
905	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. 2015 , 13, 374	11
904	Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. 2015 , 17, 124	151
903	An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. 2015 , 17, 131	50
902	Gene expression meta-analysis reveals immune response convergence on the IFN γ STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. 2015 , 7, 96	13
901	Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia. 2015 , 90, E219-20	0
900	Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?. 2015 , 262, 476-85; discussion 483-5	114
899	Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. 2015 , 112, 421-6	29

898	HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era. 2015 , 58, 1130-6	22
897	Prognostic role of tumour-infiltrating inflammatory cells in brain tumours: literature review. 2015 , 28, 647-58	25
896	Targeting PD-1/PD-L1 in lung cancer: current perspectives. 2015 , 6, 55-70	9
895	Cancer stem cell plasticity and tumor hierarchy. 2015 , 7, 27-36	163
894	Clinical and prognostic significance of pathological and inflammatory markers in the surgical treatment of locally advanced colorectal cancer. 2015 , 8, 2329-37	4
893	Combined therapy for gastrointestinal carcinomas: exploiting synergies between gene therapy and classical chemo-radiotherapy. 2015 , 15, 151-60	6
892	CARACTERIZACIÓN DEL INFILTRADO LINFOCITARIO (CD3, CD4, CD8, CD45RO Y FOXP3) E INESTABILIDAD MICRO-SATELITAL EN PACIENTES CON CÁNCER COLORRECTAL. 2015 , 67, 43-50	1
891	Gastric cancer and the epoch of immunotherapy approaches. 2015 , 21, 5778-93	67
890	Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. 2015 , 6, 12369-82	46
889	Neoadjuvant therapy for melanoma: a promising therapeutic approach and an ideal platform in drug development. 2015 , e535-42	5
888	Bioinformatics Mining and Modeling Methods for the Identification of Disease Mechanisms in Neurodegenerative Disorders. 2015 , 16, 29179-206	37
887	HPV Carcinomas in Immunocompromised Patients. 2015 , 4, 260-81	67
886	Editorial: "Recent Advances in Gamma/Delta T Cell Biology: New Ligands, New Functions, and New Translational Perspectives". 2015 , 6, 371	28
885	Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. 2015 , 6, 424	12
884	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. 2015 , 5, 152	24
883	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. 2015 , 5, 202	154
882	ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW. 2015 , 61, 13-22	13
881	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. 2015 , 2, 15048	6

880	Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. 2015 , 21, 1207-15	61
879	Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. 2015 , 3, 771-802	9
878	Image analyzer-based assessment of tumor-infiltrating T cell subsets and their prognostic values in colorectal carcinomas. 2015 , 10, e0122183	27
877	Specific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasis. 2015 , 10, e0122374	28
876	T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols. 2015 , 10, e0122723	25
875	Whole Body Melanoma Transcriptome Response in Medaka. 2015 , 10, e0143057	13
874	Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer. 2015 , 10, e0143370	28
873	Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma. 2015 , 10, e0144192	48
872	[When antibodies meet anti-tumor immunity: end of the game for tumor cells?]. 2015 , 31, 707-8	0
871	Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. 2015 , 2015, 158038	42
870	Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. 2015 , 2015, 308574	23
869	From mice to humans: developments in cancer immunoediting. 2015 , 125, 3338-46	188
868	Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site. 2015 , 6, 27832-46	30
867	Whole-transcriptome analysis of flow-sorted cervical cancer samples reveals that B cell expressed TCL1A is correlated with improved survival. 2015 , 6, 38681-94	11
866	Tumor Biology: Is It Time to Redefine Unresectability? An Extraordinary Case of Gastroesophageal Junctional Adenocarcinoma. 2015 , 7, e420	
865	Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. 2015 , 15, 521-9	8
864	Immune cell profiling to guide therapeutic decisions in rheumatic diseases. 2015 , 11, 541-51	51
863	Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. 2015 , 4, e1005460	25

862	T cell exclusion, immune privilege, and the tumor microenvironment. <i>Science</i> , 2015 , 348, 74-80	33.3	1156
861	High-resolution genomic analysis: the tumor-immune interface comes into focus. 2015 , 16, 65		3
860	Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotherapy. 2015 , 263-282		
859	Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment. 2015 , 4, e978709		26
858	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. 2015 , 21, 3347-3355		184
857	Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. 2015 , 42, 549-61		33
856	Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. 2015 , 3, 345-55		402
855	Prognostic value of CD45RO(+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30 Gy/10f neoadjuvant radiotherapy. 2015 , 30, 753-60		10
854	Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. 2015 , 17, 30		8
853	Immune modulation in advanced radiotherapies: Targeting out-of-field effects. 2015 , 368, 246-51		34
852	Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases. 2015 , 3, 380-8		24
851	High Expression of Major Histocompatibility Complex Class I in Clear Cell Renal Cell Carcinoma Is Associated with Improved Prognosis. 2015 , 95, 72-8		2
850	CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder. 2015 , 194, 556-62		92
849	Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. 2015 , 4, e965570		141
848	Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. 2015 , 75, 3446-55		148
847	Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia. 2015 , 49, 1057-67		42
846	Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. 2015 , 113, 1677-86		50
845	Developments in T Cell Based Cancer Immunotherapies. 2015 ,		

844	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. 2015 , 99-127	4
843	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). 2015 , 4, e1049804	34
842	The antigenic repertoire of premalignant and high-risk lesions. 2015 , 8, 266-70	12
841	Le système immunitaire dans la carcinogénèse colorectale : ami ou ennemi ?. 2015 , 9, 217-223	
840	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. 2015 , 5, 257-267	
839	Lymph node harvest (LNH) in colorectal cancer; a critical appraisal. 2015 , 86, 497-504	1
838	Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression. 2015 , 64, 1487-94	38
837	[Tumor-associated macrophages: Function and differentiation]. 2015 , 36, 477-84	3
836	Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling. 2015 , 13, 2851-64	75
835	New hope on the horizon for patients with metastatic colorectal cancer. 2015 , 4, 229-239	
834	An ensemble of machine learning and anti-learning methods for predicting tumour patient survival rates. 2015 ,	1
833	Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. 2015 , 10, 3411-3418	37
832	Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies. 2015 , 245-258	
831	Recombinant Salmonella-based CEACAM6 and 4-1BBL vaccine enhances T-cell immunity and inhibits the development of colorectal cancer in rats: In vivo effects of vaccine containing 4-1BBL and CEACAM6. 2015 , 33, 2837-44	8
830	Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma. 2015 , 51, 157-65	30
829	Adoptive immunotherapy against sarcomas. 2015 , 15, 517-28	9
828	Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. 2015 , 64, 99-104	29
827	Anti-CD20 therapy induces a memory Th1 response through the IFN- γ /IL-12 axis and prevents protumor regulatory T-cell expansion in mice. 2015 , 29, 947-57	36

826	Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy. 2015 , 14, 537-49	12
825	T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses. 2015 , 23, 964-973	10
824	Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice. 2015 , 136, 2588-97	4
823	Plasmacytoid dendritic cells, a role in neoplastic prevention and progression. 2015 , 45 Suppl 1, 1-8	36
822	Targeting the tumor vasculature to enhance T cell activity. 2015 , 33, 55-63	169
821	Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells. 2015 , 3, 116-24	25
820	Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. 2015 , 45, 922-31	60
819	Innate immune recognition of cancer. 2015 , 33, 445-74	323
818	Defensins: "Simple" antimicrobial peptides or broad-spectrum molecules?. 2015 , 26, 361-70	84
817	The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. 2015 , 149, 587-96	24
816	Immune escape mechanisms as a guide for cancer immunotherapy. 2015 , 21, 687-92	523
815	New perspectives on type I IFNs in cancer. 2015 , 26, 175-8	43
814	Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. 2015 , 31, 557-74	62
813	Inducible RNAi in vivo reveals that the transcription factor BATF is required to initiate but not maintain CD8+ T-cell effector differentiation. 2015 , 112, 512-7	22
812	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. 2015 , 67, 46-57	81
811	Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment. 2015 , 23, 396-406	18
810	Molecular mechanisms of CD8(+) T cell trafficking and localization. 2015 , 72, 2461-73	47
809	Building immunity to cancer with radiation therapy. 2015 , 368, 198-208	57

808	Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. 2015 , 28, 766-77	79
807	Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics. 2015 , 194, 2049-56	92
806	Increased number of forkhead box P3+ tumor-infiltrating lymphocytes correlates with high preoperative albumin level and better survival in patients with stage II or III colorectal cancer. 2015 , 36, 5407-14	12
805	Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration. 2015 , 20, 913-21	5
804	Low infiltration of peritumoral regulatory T cells predicts worse outcome following resection of colorectal liver metastases. 2015 , 22, 180-6	31
803	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. 2015 , 21, 3031-40	249
802	A clinical model for predicting lymph node metastasis in submucosal invasive (T1) colorectal cancer. 2015 , 30, 761-8	25
801	Quoi de neuf en coloproctologie depuis la fin du dernier millénaire ? L'anatomie pathologique et la pathologie tumorale maligne colorectale. 2015 , 9, 41-47	
800	The role of oncolytic virus immunotherapies to subvert cancer immune evasion. 2015 , 11, 675-89	15
799	Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. 2015 , 112, 1027-36	36
798	Inflammatory and redox reactions in colorectal carcinogenesis. 2015 , 1340, 95-103	48
797	T Cell-Based Gene Therapy of Cancer. 2015 , 281-304	
796	The immune response in cancer: from immunology to pathology to immunotherapy. 2015 , 467, 127-35	42
795	Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine. 2015 , 5, 11275	10
794	Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions. 2014 , 4, 378	2
793	High APOBEC3B expression is a predictor of recurrence in patients with low-risk clear cell renal cell carcinoma. 2015 , 33, 340.e1-8	27
792	Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. 2015 , 6, 67	94
791	Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. 2015 , 128, 263-307	85

790	Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. 2015 , 149, 1177-1190.e3	259
789	The prognostic value of plasma soluble CD40 ligand levels in patients with nasopharyngeal carcinoma. 2015 , 447, 66-70	7
788	Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. 2015 , 11, 125-140	21
787	Regulatory T-cell Response to Enterotoxigenic Bacteroides fragilis Colonization Triggers IL17-Dependent Colon Carcinogenesis. 2015 , 5, 1098-109	98
786	Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. 2015 , 128, 141-71	58
785	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. 2015 , 113, 786-93	16
784	High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. 2015 , 4, e974374	45
783	Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour. 2015 , 113, 204-11	81
782	Cancer Immunity: Lessons From Infectious Diseases. 2015 , 212 Suppl 1, S67-73	24
781	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2R β Immunodeficient Mice. 2015 , 75, 3466-78	98
780	The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where. 2015 , 154, 36-56	104
779	Adoptive T-cell therapy: a need for standard immune monitoring. 2015 , 7, 513-33	16
778	Intravital and whole-organ imaging reveals capture of melanoma-derived antigen by lymph node subcapsular macrophages leading to widespread deposition on follicular dendritic cells. 2015 , 6, 114	25
777	Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. 2015 , 166, 721-732.e1	70
776	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. 2015 , 33, 7415-7422	116
775	Changes of immunocytic phenotypes and functions from human colorectal adenomatous stage to cancerous stage: Update. 2015 , 220, 1186-96	17
774	Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. 2015 , 4, e30	33
773	Tumor Immunology, toward a Success Story?. 2015 , 6, 65	1

772	T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response. 2015 , 64, 1369-81	5
771	Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. 2015 , 34, 5960-70	57
770	The prognostic landscape of genes and infiltrating immune cells across human cancers. 2015 , 21, 938-945	1541
769	PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma. 2015 , 7, 338-50	10
768	H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance. 2015 , 195, 1868-82	64
767	Understanding high endothelial venules: Lessons for cancer immunology. 2015 , 4, e1008791	55
766	Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?. 2015 , 5, 250-256	6
765	DNA-Demethylating Agents Enhance Cytolytic Activity of CD8 T Cells and Anti-Tumor Immunity.	
764	Pan-cancer deconvolution of cellular composition identifies molecular correlates of antitumour immunity and checkpoint blockade response.	
763	Classifications moléculaires et immunes des cancers colorectaux : implication pour la prise en charge clinique. 2018 , 12, 138-144	
762	Autotransplantation of T-lymphocytes as a tool for antigen-specific immunotherapy of oncological diseases. 2018 , 20, 95-104	1
761	Infiltration of CD8+ T cells into tumor-cell clusters in Triple Negative Breast Cancer.	
760	Cellular Immunotherapy for Sarcomas. 2019 , 139-152	
759	Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer. 2019 , 62, 127-130	0
758	Tissue and Circulating Biomarkers in Mesothelioma. 2019 , 123-138	
757	Development of Human Neuroblastomas in Mouse-Human Neural Crest Chimeras.	
756	Immunoproteomic Biomarkers: From Publication to Personalized Medicine. 2019 , 2024, 371-377	
755	Das Immunsystem und Krebs. 2019 , 13-29	

754 KANSER GELİMİNDE İNFLAMASYONUN ROLÜ

753 Lymph Node Status in Colorectal Cancer; Is There a Case for Auditing the Pathologist and the Surgeon?. **2019**, In Press,

752 Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study (Preprint). 1

751 Clinical Trials and Novel/Emerging Treatment. **2019**, 183-208 1

750 The Watch and Wait Approach After Neoadjuvant Therapy: The Australian Viewpoint. **2019**, 213-230

749 The Expression of CD155 on Renal Cell Carcinoma Cells. **2019**, 09, 373-381

748 Dynamic visualization of the whole process of cytotoxic T lymphocytes killing B16 tumor cells in vitro. **2019**, 24, 1-7 3

747 Immunogenomic landscape of hematological malignancies.

746 Yap suppresses T cell function and infiltration in the tumor microenvironment.

745 A Single-Cell Immune Atlas of Triple Negative Breast Cancer Reveals Novel Immune Cell Subsets. 2

744 Gene prediction in heterogeneous cancer tissues and establishment of Least Absolute Shrinking and Selection Operator model of lung squamous cell carcinoma.

743 Functional Genome Profiling to Understand Cancer Immune Responsiveness. **2020**, 2055, 231-244

742 Tumor-Infiltrantig Lymphocytes Density as Determinant in Early Stage Colorectal Cancer Prognosis: A Single Centre Pilot Study. **2019**, 1-5

741 Immunotherapy in the Management of Colorectal Cancer Liver Metastasis. **2020**, 269-282

740 The Biology of Colorectal Liver Metastases. **2020**, 7-20

739 Stress, Inflammation and Cancer Prognosis: New Evidence-Based Effective Treatments. **2019**, 13, 150-155

738 The Current Use of Biomedical Cell Products for Cancer Treatment. **2019**, 19, 206-214

737 Prognostic Value of Innate and Adaptive Immunity in Cancers. **2020**, 403-415

736	The Roles of CD4+ T-Cells in Tumor Immunity. 2020 , 63-90	
735	Identification of Immunological Features Enables Survival Prediction of Muscle-Invasive Bladder Cancer Patients Using Machine Learning.	1
734	Prognostic and predictive role of the tumor immune landscape. 2020 , 64, 143-151	1
733	Systemic inflammation markers in blood samples of colorectal cancer patients. 2020 , 10, 92-101	
732	A REVIEW OF MODERN IMMUNOTHERAPY IN GASTROINTESTINAL MALIGNANT TUMORS. 2020 , 6, 9-21	
731	Cellular heterogeneity map of diverse immune and stromal phenotypes within breast tumor microenvironment. 2020 , 8, e9478	2
730	Novel Immunotherapeutic Approach in Gastric Cancer. 2020 , 47, 47-54	0
729	Neural Stem Cells Secreting Bispecific T Cell Engager to Induce Selective Anti-Glioma Activity.	
728	Transient cell-in-cell formation underlies tumor resistance to immunotherapy.	0
727	Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotherapy. 2021 , 251-271	
726	MAIT cell tumor infiltration predicts long-term survival in cholangiocarcinoma. 2021 ,	1
725	Developing a Clinical Workflow That Fits Your Needs. 2022 , 81-93	
724	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. 2021 , 13,	0
723	Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey. 2021 , 13,	
722	Tumor Microenvironment Profiles Reveal Distinct Therapy-Oriented Proteogenomic Characteristics in Colorectal Cancer. 2021 , 9, 757378	1
721	Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer. 2021 , 2021, 8686307	2
720	Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma. 2021 , 21, 1165	0
719	Study Protocol of A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localized Rectal Cancer.	

- 718 The Biology of Immune-Active Cancers and Their Regulatory Mechanisms. **2020**, 180, 149-172 0
- 717 Correlation analysis of the proportion of monocytic myeloid-derived suppressor cells in colorectal cancer patients. **2020**, 15, e0243643 2
- 716 Companion Diagnostics and Clinical Biomarkers for Immunotherapy. **2021**, 137-152
- 715 Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment. **2020**, 8, 5935-5943 1
- 714 Characterizing Immune Responses in Whole Slide Images of Cancer With Digital Pathology and Pathomics. **2020**, 8, 133-148 3
- 713 Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment. **2020**, 8, 5932-5940
- 712 Association of cytotoxic T lymphocyte-associated protein 4 gene -1772T/C polymorphism with gastric cancer risk: A prisma-compliant meta-analysis. **2020**, 99, e23542 0
- 711 CRC: A Darwinian model of cellular immunoselection. **2022**, 529-541
- 710 Neutrophil-to-Lymphocyte Ratio and Intratumoral CD45RO-Positive T Cells as Predictive Factors for Longer Survival of Patients with Colorectal Liver Metastasis after Hepatectomy. **2020**, 251, 303-311 3
- 709 Prognostic and immunological value of LTB4R in pan-cancer. **2021**, 18, 9336-9356
- 708 Tumor-infiltrating lymphocytes in primary tumors of colorectal cancer and their metastases. **2019**, 18, 4904-4912 2
- 707 Phytochemicals Plus Checkpoint Inhibitors in GI Cancers. **2020**, 83-107
- 706 Immunohistochemistry of Cancers. **2020**, 645-709
- 705 Current Perspectives on Cancer Immunotherapy in Bone. **2020**, 421-437
- 704 The Immune Landscape in Women Cancers. **2020**, 180, 215-249 1
- 703 Immune Targets in Colorectal Cancer. **2020**, 205-230
- 702 Prognostic significance of lymph node count in high-risk node-negative colon carcinoma. **2020**, 112, 609-614
- 701 CHAPTER 10. Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities. **2020**, 259-306

- 700 Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution.
- 699 Tumor-infiltrating immune cells signature predicts recurrence free survival after complete resection of localized primary gastrointestinal stromal tumors. 1
- 698 The anti-tumour effect of CD8+ infiltration is associated with Human Leukocyte Antigen Class I expression and tumour proliferation in colorectal cancer.
- 697 Frequency-dependent interactions determine outcome of competition between two breast cancer cell lines. 2
- 696 SCENITH: A flow cytometry based method for functional profiling energy metabolism with single cell resolution.
- 695 Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients. **2021**, 12, 751594 3
- 694 PI3K Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients. **2021**, 13, 3
- 693 Correlation between schistosomiasis and CD8+ T cell and stromal PD-L1 as well as the different prognostic role of CD8+ T cell and PD-L1 in schistosomal-associated colorectal cancer and non-schistosomal-associated colorectal cancer. **2021**, 19, 321 2
- 692 The Immune Landscape of Colorectal Cancer. **2021**, 13, 1
- 691 Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. **2021**, 0
- 690 Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer. **2021**, 73, 103664 1
- 689 Cancer Vaccines and Immune Monitoring (An Overview). **2008**, 129-159
- 688 Der Verlust von CD3-zeta in Tumor-infiltrierenden T-Zellen ist ein negativer Prognosemarker für das Kolonkarzinom. **2008**, 5-7
- 687 Significance of accurate hilar and intrapulmonary lymph node examination and prognostication in stage IA-IIA non-small cell lung cancer, a retrospective cohort study. **2020**, 18, 258 1
- 686 Hurdles in Cancer Immunotherapy. **2021**, 597-635
- 685 Molecular Pathology in Colorectal Cancer: Current Practice and Future Directions. **2021**, 305-315
- 684 The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. **2021**,
- 683 Genetic Variants in the Regulatory T cell-Related Pathway and Colorectal Cancer Prognosis. **2020**, 29, 2719-2728

682	Why cancer and inflammation?. 2006 , 79, 123-30	240
681	Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. 2009 , 10, 526-35	41
680	Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. 2007 , 7, 7	104
679	Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. 2007 , 7, 12	94
678	Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. 2007 , 7, 4	199
677	The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. 2009 , 9, 1	54
676	Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. 2008 , 8, 16	68
675	Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer. 2008 , 8, 11	23
674	Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory. 2011 , 1, 882-96	9
673	Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model. 2012 , 2, 204-13	8
672	On the prognostic & predictive impact of immune cells system in colorectal cancer. 2012 , 135, 147-9	
671	MAGE-A3 is highly expressed in a subset of colorectal cancer patients. 2012 , 12, 16	32
670	NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. 2013 , 13, 12	14
669	Significance of peripheral neutrophil-lymphocyte ratio among gastric cancer patients and construction of a treatment-predictive model: a study based on 1131 cases. 2014 , 4, 189-95	24
668	Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation. 2013 , 5, 19-25	13
667	Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). 2014 , 7, 3563-79	16
666	Decreased intratumoral Foxp3 Tregs and increased dendritic cell density by neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer. 2014 , 7, 4685-94	18
665	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. 2014 , 6, S568-80	8

664	Changes of TCR repertoire diversity in colorectal cancer after Erbitux (cetuximab) in combination with chemotherapy. 2014 , 4, 924-33	9
663	Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. 2014 , 7, 7610-21	35
662	Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer. 2014 , 7, 8929-34	7
661	Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy. 2013 , 2, 415-22	2
660	Immunological parameters as a new lead in the diagnosis of ovarian cancer. 2015 , 7, 67-72	3
659	Tumor-infiltrating memory T-lymphocytes for prognostic prediction in cancer patients: a meta-analysis. 2015 , 8, 1803-13	12
658	Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. 2015 , 5, 2064-74	55
657	High intratumoral FOXP3+ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer. 2015 , 8, 8227-35	24
656	High CD4+ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer. 2015 , 8, 11510-6	10
655	IL-10: Expanding the Immune Oncology Horizon. 2015 , 2,	5
654	B7-H3 expression associates with tumor invasion and patient's poor survival in human esophageal cancer. 2015 , 7, 2646-60	25
653	CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS. 2009 , 3, 14-16	1
652	Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. 2015 , 29, 908-20, 922	46
651	Mismatch repair-based stratification for immune checkpoint blockade therapy. 2018 , 8, 1977-1988	7
650	Immune reaction by cytoreductive prostatectomy. 2019 , 7, 64-79	2
649	Improved performance of Hangzhou criteria for liver transplantation of hepatocellular carcinoma: the role of liver resident FoxP3 regulatory T cells. 2018 , 11, 1328-1337	
648	Infiltrating CD4/CD8 high T cells shows good prognostic impact in pancreatic cancer. 2017 , 10, 8820-8828	6
647	Prognostic significance of preoperative platelet-lymphocyte ratio in a Chinese cohort patient with colorectal cancer. 2017 , 10, 8686-8694	

646	Increased Plasma Cells and Decreased B-cells in Tumor Infiltrating Lymphocytes are Associated with Worse Survival in Lung Adenocarcinomas. 2020 , 11,	2
645	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. 2020 , 12, 5416-5432	4
644	POC1A acts as a promising prognostic biomarker associated with high tumor immune cell infiltration in gastric cancer. 2020 , 12, 18982-19011	1
643	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. 2020 , 12, 22509-22526	4
642	Consider the chemokines: a review of the interplay between chemokines and T cell subset function. 2017 , 24, 31-39	11
641	SIRT1 induces the accumulation of TAMs at colorectal cancer tumor sites via the CXCR4/CXCL12 axis. 2021 , 371, 104458	1
640	Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma.. 2022 , 12, 167-185	2
639	Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy. 2021 , 13,	0
638	CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer. 2021 , 11, 22495	1
637	The correlation of immunoscore and frailty in colorectal cancer. 2021 , 1	0
636	Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon Cancer. 2021 , 13,	0
635	BET Inhibition Enhances TNF-Mediated Antitumor Immunity. 2021 ,	1
634	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer. 2021 , 14, 9031-9049	
633	EMS1/DLL4-Notch Signaling Axis Augments Cell Cycle-Mediated Tumorigenesis and Progress in Human Adrenocortical Carcinoma. 2021 , 11, 771579	0
632	Biejiajian Pill Promotes the Infiltration of CD8 T Cells in Hepatocellular Carcinoma by Regulating the Expression of CCL5.. 2021 , 12, 771046	0
631	Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?. 2021 , 11, 769305	1
630	Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. 2021 , 11, 764618	1
629	Advanced technologies for single-cell in situ protein profiling. 2022 , 65, 48	4

628	Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. 2021 , 11, 773420	1
627	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. 2021 , 13,	0
626	A size and space structured model of tumor growth describes a key role for protumor immune cells in breaking equilibrium states in tumorigenesis. 2021 , 16, e0259291	0
625	Prognostic Characteristics of Colorectal Cancer Patients With Benign Mesenteric Lymph Node Enlargement: A Multi-Institutional Cohort Study. 2021 ,	1
624	Nuclear Imaging of Endogenous Markers of Lymphocyte Response. 2022 , 15-59	
623	Identification of a Five Autophagy Subtype-Related Gene Expression Pattern for Improving the Prognosis of Lung Adenocarcinoma. 2021 , 9, 756911	1
622	Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. 2021 , 12, 6726	10
621	Analysis of core genes for colorectal cancer prognosis based on immune and stromal scores. 2021 , 9, e12452	4
620	Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. 2021 , 37, 110021	2
619	Biomarkers in Locally Advanced Rectal Cancer: A Review.. 2021 ,	0
618	Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors. 2021 , 18, 2632-2647	3
617	Interaction Between Macrophage Extracellular Traps and Colon Cancer Cells Promotes Colon Cancer Invasion and Correlates With Unfavorable Prognosis.. 2021 , 12, 779325	3
616	Tumour-infiltrating bystander CD8 T cells activated by IL-15 contribute to tumour control in non-small cell lung cancer. 2021 ,	0
615	The impact of obesity and bariatric surgery on the immune microenvironment of the endometrium. 2021 ,	1
614	A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. 2021 , 159, 247-258	1
613	Proliferating CD8 T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma.. 2021 , 10,	3
612	The Ratio of Cytotoxic Lymphocytes to M2-Like Macrophages is Prognostic in Immunogenic Tumors and Predicts Immunotherapy Response.	
611	Immune System in Action.. 2021 , 1342, 1-43	

610	External stimuli-responsive nanomedicine for cancer immunotherapy. 2021 ,		
609	Description and Interpretation of Results; The Pathology Report. 2021 , 125-136		
608	Prognostic value of LINC02560 in colorectal cancer correlates with tumor microenvironment immunity.. 2021 , 12, 7507-7517		1
607	PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis. 2021 , 15, 680-696		3
606	Tertiary lymphoid structures in cancer.. <i>Science</i> , 2022 , 375, eabf9419	33.3	19
605	Harnessing Antitumor CD4 T Cells for Cancer Immunotherapy.. 2022 , 14,		3
604	Enhancing the HSV-1-mediated antitumor immune response by suppressing Bach1.. 2022 ,		
603	Biomarkers in Gastrointestinal System Carcinomas. 2022 , 165-199		
602	Prognostic biomarkers of cutaneous melanoma.. 2022 ,		0
601	NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models.. 2021 , 16, 101322		2
600	POC1A acts as a promising prognostic biomarker associated with high tumor immune cell infiltration in gastric cancer. 2020 , 12, 18982-19011		1
599	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. 2020 , 12, 22509-22526		4
598	Biomarkers for Immunotherapy in Gastrointestinal Cancers. 2021 ,		
597	Identification and Validation of an EMT-Related LncRNA Signature for HNSCC to Predict Survival and Immune Landscapes.. 2021 , 9, 798898		0
596	An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.. 2022 , 22, 62		0
595	Prognostic Bone Metastasis-Associated Immune-Related Genes Regulated by Transcription Factors in Mesothelioma.. 2022 , 2022, 9940566		0
594	Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.. 2022 , 12, 5		2
593	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.. 2021 , 12, 808964		4

592	PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma.. 2022 , 156, 453	
591	CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets.. 2021 , 11, 808396	0
590	Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.. 2021 , 12, 798424	1
589	PET/CT Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients.. 2021 , 11, 802257	0
588	Metachronous colorectal cancer have a similar microsatellite instability frequency but a lower infiltration of lymphomononuclear cells than primary lesions.. 2022 ,	
587	Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer.. 2022 , 22, 44	4
586	Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma.. 2022 , 1	0
585	Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence.. 2022 ,	0
584	Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns.. 2022 ,	1
583	Identification of Tumor Antigens and Design of mRNA Vaccine for Colorectal Cancer Based on the Immune Subtype.. 2021 , 9, 783527	2
582	Development of Personalized Signature Based on the Immune Landscape to Predict the Prognosis of Osteosarcoma and the Response to Immunotherapy and Targeted Therapy.. 2021 , 8, 783915	
581	The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.. 2021 , 12, 802049	0
580	Quantifying and correcting slide-to-slide variation in multiplexed immunofluorescence images.. 2022 ,	2
579	Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment.. 2022 , 12, 1678	1
578	Spatial Metrics of Interaction between CD163-Positive Macrophages and Cancer Cells and Progression-Free Survival in Chemo-Treated Breast Cancer.. 2022 , 14,	1
577	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.. 2021 , 12, 799455	7
576	Deconvolving clinically relevant cellular immune crosstalk from bulk gene expression using CODEFACS and LIRICS stratifies melanoma patients to anti-PD-1 therapy.. 2022 ,	2
575	Identification and Validation of Immune-Related Prognostic Genes in the Tumor Microenvironment of Colon Adenocarcinoma.. 2021 , 12, 778153	

574	Ablation of T cell-associated PD-1H enhances functionality and promotes adoptive immunotherapy.. 2021 ,	0
573	A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resection.. 2022 , 11, 24-42	0
572	Discovering dominant tumor immune archetypes in a pan-cancer census.. 2021 ,	10
571	Pan-Cancer Study on Protein Kinase C Family as a Potential Biomarker for the Tumors Immune Landscape and the Response to Immunotherapy.. 2021 , 9, 798319	1
570	The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density.. 2022 , 13, 781222	0
569	Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study.. 2022 , 4, e8-e17	3
568	Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data.. 2022 , 12,	2
567	Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses.. 2022 ,	3
566	Novel Mouse Models for Cancer Immunology. 2022 , 6,	0
565	Immunomodulatory properties of nanostructured systems for cancer therapy.. 2022 ,	0
564	FPIA: A database for gene fusion profiling and interactive analyses.. 2022 ,	1
563	An Immune Feature-Based, Three-Gene Scoring System for Prognostic Prediction of Head-and-Neck Squamous Cell Carcinoma.. 2021 , 11, 739182	0
562	The Radiobiology of TGF β 2022 ,	2
561	Identifying Potential Biomarkers of Prognostic Value in Colorectal Cancer Tumor Microenvironment Data Mining.. 2021 , 12, 787208	1
560	Ig-h3-structured collagen alters macrophage phenotype and function in pancreatic cancer.. 2022 , 25, 103758	1
559	Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer.. 2022 , 172, 16-16	0
558	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.. 2022 , 236, 108111	6
557	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies.. 2022 ,	

556	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.. 2022 , 12,	3
555	Classification of early-stage colon cancer with Immunoscore: clinical evidence and case studies.. 2021 ,	1
554	Inflammatory Related Reactions in Humans and in Canine Breast Cancers, A Spontaneous Animal Model of Disease.. 2022 , 13, 752098	2
553	Emerging new therapeutic antibody derivatives for cancer treatment.. 2022 , 7, 39	18
552	The immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.. 2021 ,	0
551	Post-transplant malignancies show reduced T-cell abundance and tertiary lymphoid structures as correlates of impaired cancer immunosurveillance.. 2022 ,	1
550	Mast cell density and its clinical relevance in Waldenström's macroglobulinemia.	
549	An Asian-specific variant in human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment.. 2022 ,	0
548	Chemokines network in bone metastasis: Vital regulators of seeding and soiling.. 2022 ,	1
547	CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle.. 2022 , 20, 78	3
546	Functional and molecular characterization of PD1 tumor-infiltrating lymphocytes from lung cancer patients.. 2022 , 11, 2019466	0
545	Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy.. 2022 , 23, 127-133	2
544	Immune sunrise: from the immunome to the cancer immune landscape.. 2022 , 11, 2019896	1
543	Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients.. 2022 , 13, 811007	0
542	CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy.. 2022 , 1-10	
541	Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer.. 2022 , 3, 108-121	9
540	Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma.. 2021 , 11, 793808	0
539	Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression.. 2022 , 113, 89-106	0

538	BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC.. 2022 , 13, 2126-2137	2
537	Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.. 2022 , 14, 17588359221077972	2
536	Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody.. 2022 , 22, e4	3
535	Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.. 2022 , 10,	2
534	Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma.. 2022 , 6, 10	0
533	LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.. 2022 ,	0
532	Identification of the Crucial Role of CCL22 in -Related Colorectal Tumorigenesis that Correlates With Tumor Microenvironment and Immune Checkpoint Therapy.. 2022 , 13, 811900	1
531	Neutrophil extracellular traps drive epithelial-mesenchymal transition of human colon cancer.. 2021 ,	4
530	The Importance of Being "That" Colorectal pT1: A Combined Clinico-Pathological Predictive Score to Improve Nodal Risk Stratification.. 2022 , 9, 837876	0
529	Multi-faced roles of reactive oxygen species in anti-tumor T cell immune responses and combination immunotherapy. 77-98	1
528	Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring.. 2022 , 14,	0
527	The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.. 2022 , 14,	0
526	Notch signaling in tumor vasculature programs cancer-associated fibroblasts to suppress anti-tumor immunity.	
525	First passage time analysis of spatial mutation patterns reveals evolutionary dynamics of pre-existing resistance in colorectal cancer.	
524	Analysis of Gene Co-Expression Network to Identify the Role of CD8 + T Cell Infiltration-Related Biomarkers in High-Grade Glioma.. 2022 , 15, 1879-1890	0
523	The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.. 2022 , 14,	3
522	The Unfolded Protein Response at the Tumor-Immune Interface.. 2022 , 13, 823157	1
521	Deep Learning-Based Mapping of Tumor Infiltrating Lymphocytes in Whole Slide Images of 23 Types of Cancer.. 2021 , 11, 806603	5

520	Artificial intelligence to identify genetic alterations in conventional histopathology.. 2022,	1
519	HSPB8 is a Potential Prognostic Biomarker that Correlates With Immune Cell Infiltration in Bladder Cancer.. 2022, 13, 804858	
518	A Coculture Model Mimicking the Tumor Microenvironment Unveils Mutual Interactions between Immune Cell Subtypes and the Human Seminoma Cell Line TCam-2.. 2022, 11,	1
517	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.. 2022, 15, 24	8
516	Development and Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small Cell Lung Cancer.. 2022, 13, 835630	
515	A Potential Diagnostic and Prognostic Biomarker TMEM176B and Its Relationship With Immune Infiltration in Skin Cutaneous Melanoma.. 2022, 10, 859958	0
514	lLnc: Prioritizing Long Non-coding RNAs for Pan-cancer Analysis of Immune Cell Infiltration.	
513	Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy.. 2022, 10,	0
512	Evaluation of Microscopic Tumour Extension in Localized Stage Non-Small-Cell Lung Cancer for Stereotactic Radiotherapy Planning.. 2022, 14,	
511	Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?. 2022, 14,	1
510	Harnessing the chemokine system to home CAR-T cells into solid tumors.. 2022, 3, 100543	1
509	Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors.. 2022, 13, 849759	0
508	Proposed Models for Prediction of Mortality in Stage-I and Stage-II Gastric Cancer and 5 Years after Radical Gastrectomy.. 2022, 2022, 4510000	2
507	Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.. 2022, 11, 2046931	3
506	In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.. 2022, 10,	1
505	A novel inflammation-related prognostic biomarker for predicting the disease-free survival of patients with colorectal cancer.. 2022, 20, 79	1
504	BAP1-Related ceRNA (NEAT1/miR-10a-5p/SERPINE1) Promotes Proliferation and Migration of Kidney Cancer Cells.. 2022, 12, 852515	1
503	Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?. 2022, 23,	0

502	Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma.. 2022 , 6, 17	0
501	Exploration of Reduced Mitochondrial Content-Associated Gene Signature and Immunocyte Infiltration in Colon Adenocarcinoma by an Integrated Bioinformatic Analysis.. 2022 , 13, 832331	0
500	How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.. 2022 , 108962	1
499	Multiplexed single-cell analysis reveals prognostic and non-prognostic T cell types in human colorectal cancer.. 2022 ,	1
498	Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer.. 2022 , 166, 189-196	1
497	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.. 2022 ,	7
496	Immunosuppressive niche engineering at the onset of human colorectal cancer.. 2022 , 13, 1798	0
495	Prediction of Survival Rate and Chemotherapy Effect by an Immune Score Model in Colorectal Cancer.. 2022 , 2022, 8219701	
494	Computer extracted features of tumor-infiltrating lymphocytes (TILs) architecture are prognostic of progression-free survival in stage III colon cancer. 2022 ,	
493	New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis.. 2022 , 10,	1
492	The Comparable Microenvironment Shared by Colorectal Adenoma and Carcinoma: An Evidence of Stromal Proteomics.. 2022 , 12, 848782	0
491	The solid tumor microenvironment-Breaking the barrier for T cells: How the solid tumor microenvironment influences T cells: How the solid tumor microenvironment influences T cells.. 2022 , e2100285	0
490	Tumor-associated CD3- and CD8-positive immune cells in colorectal cancer: The additional prognostic value of CD8+to-CD3+ ratio remains debatable.. 2022 , 44, 37-52	1
489	Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.. 2022 , 173, 103663	4
488	CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities.. 2022 , 25, 69-77	4
487	Three-dimensional tumour microenvironment reconstruction and tumour-immune interactions' analysis. 2021 ,	1
486	Pathological Features and Prognostication in Colorectal Cancer.. 2021 , 28, 5356-5383	2
485	Integrin α (CD103) In Epithelial Cancer.. 2021 , 13,	0

484	Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer.. 2021 , 13, 25518-25549	0
483	Identification of Candidate Target Genes and Immune Cells in Oral Squamous Cell Carcinoma.. 2021 , 2021, 5802110	0
482	T Cell Aging in Patients with Colorectal Cancer-What Do We Know So Far?. 2021 , 13,	1
481	Macrophages play a role in inflammatory transformation of colorectal cancer.. 2021 , 13, 2013-2028	1
480	Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma.. 2021 , 1	2
479	Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry.. 2021 , 19, 529	0
478	Immune Score Predicts Outcomes of Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy.. 2021 , 2021, 9344124	2
477	Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B.. 2021 , 16, e0262198	0
476	Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.. 2021 , 13,	2
475	OX40 agonism enhances efficacy of PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.	
474	Development of a T-cell activation-related module with predictive value for the prognosis and immune checkpoint blockade therapy response in glioblastoma.. 2021 , 9, e12547	0
473	PAX5 haploinsufficiency induces low T cell infiltration in the cancer microenvironment via reduced chemokines. 2021 ,	
472	Galectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions.. 2022 , 2442, 1-40	0
471	Cell migration. 2022 , 67-82	
470	PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors.. 2022 ,	3
469	Preoperative combination score of neutrophils, monocytes, and lymphocytes as a predictor for locally advanced rectal cancer.. 2022 , 37, 1097	
468	Emerging Biomarkers for Immunotherapy in Glioblastoma.. 2022 , 14,	1
467	Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers.. 2022 , 14,	0

- 466 Human cytomegalovirus-induced immune regulation is correlated with poor prognosis in patients with colorectal cancer.. **2022**, 1 0
- 465 Prognostic significance of serum inflammation indices for different tumor infiltrative pattern types of gastric cancer.. **2022**, 14, 897-919
- 464 Identification of Potential Biomarkers for Progression and Prognosis of Bladder Cancer by Comprehensive Bioinformatics Analysis.. **2022**, 2022, 1802706 0
- 463 Genetics of Colorectal Cancer Racial Disparities.
- 462 Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.. **2022**, 167, 112-122 1
- 461 Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer.. **2022**, 7, 100470
- 460 Data_Sheet_1.docx. **2020**,
- 459 Data_Sheet_1.pdf. **2019**,
- 458 Data_Sheet_1.PDF. **2020**,
- 457 Data_Sheet_1.docx. **2020**,
- 456 Data_Sheet_1.docx. **2018**,
- 455 DataSheet_1.docx. **2020**,
- 454 Data_Sheet_1.docx. **2020**,
- 453 Data_Sheet_1.pdf. **2018**,
- 452 Data_Sheet_2.PDF. **2018**,
- 451 Data_Sheet_1.docx. **2019**,
- 450 DataSheet_1.pdf. **2019**,
- 449 Data_Sheet_1.docx. **2019**,

448 Data_Sheet_1.docx. **2019**,

447 Data_Sheet_1.docx. **2019**,

446 Image_1.JPEG. **2019**,

445 Image_2.JPEG. **2019**,

444 Image_3.JPEG. **2019**,

443 Image_4.JPEG. **2019**,

442 Image_5.JPEG. **2019**,

441 Image_6.JPEG. **2019**,

440 Image_7.JPEG. **2019**,

439 Image_8.JPEG. **2019**,

438 Image_9.JPEG. **2019**,

437 Table_1.XLSX. **2019**,

436 Table_2.XLSX. **2019**,

435 Table_3.XLSX. **2019**,

434 DataSheet_1.pdf. **2020**,

433 Data_Sheet_1.PDF. **2020**,

432 Data_Sheet_1.docx. **2020**,

431 Data_Sheet_1.docx. **2020**,

430 Table_1.docx. **2020**,

429 Table_2.docx. **2020**,

428 Data_Sheet_1.pdf. **2019**,

427 Table_1.docx. **2020**,

426 Image_1.TIF. **2020**,

425 Image_2.TIF. **2020**,

424 Image_3.TIF. **2020**,

423 Image_4.TIF. **2020**,

422 Image_5.TIF. **2020**,

421 Table_1.DOCX. **2020**,

420 Table_2.DOCX. **2020**,

419 Table_3.DOCX. **2020**,

418 Table_4.DOCX. **2020**,

417 Table_5.DOCX. **2020**,

416 Table_1.DOCX. **2020**,

415 Tissue-resident memory T cells in gastrointestinal cancer immunology and immunotherapy: ready for prime time?. **2022**, 10, ○

414 Negative Effects of Stromal Neutrophils on T Cells Reduce Survival in Resectable Urothelial Carcinoma of the Bladder.. **2022**, 13, 827457 ○

413 [Establishment of a prediction model for colorectal cancer immune cell infiltration based on the cancer genome atlas (TCGA) database].. **2022**, 54, 203-208

412	Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy.. 2022 , 12, 3488-3502	1
411	Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.. 2022 , 13, 869488	0
410	Bacterial lipopolysaccharide modulates immune response in the colorectal tumor microenvironment.	
409	In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.. 2022 , 219,	2
408	The JMJD Family Histone Demethylases in Crosstalk Between Inflammation and Cancer.. 2022 , 13, 881396	1
407	The Immune Microenvironment in Gastric Cancer: Prognostic Prediction.. 2022 , 12, 836389	0
406	Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression.. 2022 , 14,	2
405	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine.. 2022 , 14,	1
404	Resistance Mechanisms to Anti-PD Cancer Immunotherapy.. 2022 , 40, 45-74	3
403	Role of Metabolism in Adoptive T Cell Therapy: Strategies and Challenges.. 2022 ,	0
402	An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma. 2022 , 13,	1
401	New Insights into Adjuvant Therapy for Localized Colon Cancer.. 2022 ,	
400	A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies.. 2022 , 13, 2366	0
399	Olfactory Receptor OR2H1 is an effective target for CAR T cells in human epithelial tumors.. 2022 ,	0
398	Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology. 2022 , 13,	
397	Tumor Stroma Ratio and Its Significance in Locally Advanced Colorectal Cancer. 2022 , 29, 3232-3241	1
396	Data-rich spatial profiling of cancer tissue: Astronomy informs Pathology.. 2022 ,	0
395	Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer.. 2022 , 13, 875764	0

394	Comprehensive Analyses of Stromal-Immune Score-Related Competing Endogenous RNA Networks In Colon Adenocarcinoma. 2022 , 2022, 1-12	1
393	Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. 2022 , 13,	0
392	Development and validation of apoptosis-related signature and molecular subtype to improve prognosis prediction in osteosarcoma patients.. 2022 , e24501	0
391	Prognostic significance of CD8+ tumor-infiltrating lymphocytes and CD66b+ tumor-associated neutrophils in the invasive margins of stages I-III colorectal cancer. 2022 , 24,	0
390	Cancer vaccines: past, present and future; a review article.. 2022 , 13, 31	1
389	CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT.. 2022 ,	0
388	A novel four-gene signature predicts immunotherapy response of patients with different cancers.. 2022 , e24494	1
387	Correlation of clinical, pathologic, and genetic parameters with intratumoral immune milieu in mucinous adenocarcinoma of the colon.. 2022 ,	0
386	Cancer Immunoediting in the Era of Immuno-oncology.. 2022 ,	0
385	Biomarkers for Cancer Immunotherapy. 2022 , 229-247	
384	Biological and Clinicopathological Characteristics of OPN in Cervical Cancers. 2022 , 13,	
383	Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. 2022 ,	5
382	A dual-responsive doxorubicin-indoximod conjugate for programmed chemoimmunotherapy.	
381	The Immun-Enhancing and Synergistic Antitumor Efficacy of Lienal Polypeptide Combined with EGFR-TKIs for Advanced NSCLC.	
380	Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. 2022 , 12,	
379	Prognostic and clinical significance of subcellular CDC27 for patients with rectal adenocarcinoma treated with adjuvant chemotherapy. 2022 , 24,	
378	T cell Egress via Lymphatic Vessels Limits the Intratumoral T cell Repertoire in Melanoma.	0
377	Identification of Senescence-Related Subtypes, the Development of a Prognosis Model, and Characterization of Immune Infiltration and Gut Microbiota in Colorectal Cancer. 9,	1

376	Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response. 2022 , 14, 2525	0
375	Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. 2022 , 20,	1
374	A Novel Prognostic Score Based on Artificial Intelligence in Hepatocellular Carcinoma: A Long-Term Follow-Up Analysis. 2022 , 12,	0
373	ASCL2 Affects the Efficacy of Immunotherapy in Colon Adenocarcinoma Based on Single-Cell RNA Sequencing Analysis. 2022 , 13,	
372	Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE). 2022 , 13,	1
371	Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications. 2022 , 13,	0
370	Deep learning with whole slide images can improve the prognostic risk stratification with stage III colorectal cancer. 2022 , 221, 106914	1
369	An innate IL-25 \rightarrow ILC2 \rightarrow MDC axis creates a cancer-permissive microenvironment for Apc mutation-driven intestinal tumorigenesis. 2022 , 7,	2
368	News in immunotherapy of dMMR/MSI-H CRC. 2022 , 16, 118-122	
367	Taming metabolic competition via glycolysis inhibition for safe and potent tumor immunotherapy. 2022 , 115153	1
366	A Fraction of CD8+ T Cells from Colorectal Liver Metastases Preferentially Repopulate Autologous Patient-Derived Xenograft Tumors as Tissue-Resident Memory T Cells. 2022 , 14, 2882	1
365	Development of a Fully Automated Method to Obtain Reproducible Lymphocyte Counts in Patients With Colorectal Cancer. Publish Ahead of Print,	
364	Exploring the Relationship Between Senescence and Colorectal Cancer in Prognosis, Immunity, and Treatment. 13,	
363	Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer. 13,	0
362	CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy. 2022 , 22,	
361	Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome.	0
360	Immunomodulation of Melanoma by Chemo-Thermo-Immunotherapy Using Conjugates of Melanogenesis Substrate NPrCAP and Magnetite Nanoparticles: A Review. 2022 , 23, 6457	0
359	Cancer-associated fibroblasts suppress CD8+ T cell infiltration and confer resistance to immune checkpoint blockade.	2

358	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.	9
357	Prognostic Values of Combined Ratios of White Blood Cells in Glioblastoma: A Retrospective Study. 2022 , 11, 3397	2
356	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. 2022 , 132,	0
355	Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. 13,	0
354	Tumor-infiltrating OX40+ lymphocytes is an independent positive prognostic factor for patients with pancreatic ductal adenocarcinoma.	
353	The Danse Macabre: Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes. 13,	0
352	Myeloid-derived suppressor cell dynamics control outcomes in the metastatic niche.	
351	ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain. 2022 , 74, 797-822	1
350	A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration. 2022 , 2022, 1-23	
349	Novel Hypoxia-Associated Gene Signature Depicts Tumor Immune Microenvironment and Predicts Prognosis of Colon Cancer Patients. 13,	0
348	Circulating Lymphocytes Reflect the Local Immune Response in Patients with Colorectal Carcinoma. 2022 , 12, 1408	1
347	Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities. 2022 , 329-344	
346	Role of Lymphocytes in Cancer Immunity and Immune Evasion Mechanisms. 2022 , 159-182	
345	Artificial Intelligence in Studies of Malignant Tumours. 2022 , 365-375	
344	A combination of stromal PD-L1 and tumoral nuclear β -catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.	0
343	The immune landscape of solid pediatric tumors. 2022 , 41,	1
342	Intratumoral mregDC and CXCL13 T helper niches enable local differentiation of CD8 T cells following PD-1 blockade.	1
341	Analysis of the Equilibrium Phase in Immune-Controlled Tumors Provides Hints for Designing Better Strategies for Cancer Treatment. 12,	

340	Multiplex Tissue Imaging: Spatial Revelations in the Tumor Microenvironment. 2022 , 14, 3170	1
339	Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors. 2022 , 23, 7325	1
338	Programmed death-ligand 1 expression in the immune compartment of colon carcinoma.	0
337	BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer. 2022 , 23, 7158	0
336	Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.	
335	Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. 2022 , 14, 3213	1
334	Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications. 2022 , 12, 1659	
333	The efficient circulating immunoscore predicts prognosis of patients with advanced gastrointestinal cancer. 2022 , 20,	2
332	Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. 13,	1
331	Radiomics model based on multi-sequence MR images for predicting preoperative immunoscore in rectal cancer.	2
330	Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. 2022 ,	3
329	Pan-Cancer Analysis Identified Homologous Recombination Factor With OB-Fold (HROB) as a Potential Biomarker for Various Tumor Types. 13,	0
328	The Role of Inflammatory Cytokines in the Pathogenesis of Colorectal CarcinomaRecent Findings and Review. 2022 , 10, 1670	0
327	Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model.	1
326	Myeloid mechano-metabolic programming restricts anti-tumor immunity.	0
325	IL-10 and TNF α are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. 1-12	1
324	Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. 2022 , 100611	
323	Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer. 2022 , 22,	0

- 322 A deep learning and graph-based approach to characterise the immunological landscape and spatial architecture of colon cancer tissue. 0
- 321 Exercise training to increase tumour natural killer-cell infiltration in men with localised prostate cancer: a randomised controlled trial. 1
- 320 Relationship between ATOH1 and tumor microenvironment in colon adenocarcinoma patients with different microsatellite instability status. **2022**, 22,
- 319 Infiltration of Tumor Spheroids by Activated Immune Cells.
- 318 Multimolecular characteristics of cell-death related hub genes in human cancers: a comprehensive pan-cancer analysis. 1-11
- 317 Immune response in colorectal carcinoma: a review of its significance as a predictive and prognostic biomarker. 0
- 316 Dopamine signaling promotes tissue-resident memory differentiation of CD8+ T cells and antitumor immunity. 0
- 315 NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis. **2022**, 23, 7859 2
- 314 Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses. 10, 0
- 313 Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer. **2022**, 172, 221-230 1
- 312 TTYH3, a potential prognosis biomarker associated with immune infiltration and immunotherapy response in lung cancer. **2022**, 110, 108999
- 311 The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes. 3
- 310 The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. 28, 0
- 309 Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology. **2022**, 14, 3628 0
- 308 Receptor-ligand pair typing and prognostic risk model for papillary thyroid carcinoma based on single-cell sequencing. 13, 0
- 307 Immune-Endocrine Perspectives of Breast Cancer. **2022**, 22-61
- 306 CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. 13, 0
- 305 Early postoperative weight loss is associated with poor prognosis in patients with esophageal cancer.

304	Finger-powered Cell-sorting Microsystem Chip for Cancer-study Applications. 2022 , 132430	0
303	Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas.	1
302	Extracellular matrix sensing via modulation of orientational order of integrins and F-actin in focal adhesions.	
301	FGFR4-targeted chimeric antigen receptors (CARs) combined with anti-myeloid poly-pharmacy effectively treats orthotopic rhabdomyosarcoma.	3
300	La voie de signalisation de STING dans les lymphocytes T : applications potentielles en immunothérapie anticancéreuse. 2022 ,	
299	NKG7 Enhances CD8+ T Cell Synapse Efficiency to Limit Inflammation. 13,	
298	Role of Cancer-Associated fibroblast in the pathogenesis of ovarian Cancer: Focus on the latest therapeutic approaches. 2022 , 110, 109052	
297	Can granulysin provide prognostic value in primary breast cancer?. 2022 , 237, 154039	0
296	Regulation of the THRA gene, encoding the thyroid hormone nuclear receptor TR α , in intestinal lesions.	
295	Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. 12,	3
294	The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. 13,	
293	Metabolic activity via 18F-FDG PET/CT is predictive of microsatellite instability status in colorectal cancer. 2022 , 22,	0
292	Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. 2022 , 13, 907-917	
291	MUC1-mediated Macrophage Activation Promotes Colitis-associated Colorectal Cancer via Activating the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Axis. 2022 ,	1
290	Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. 2022 , 10, e004803	0
289	Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. 12,	
288	Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. 2022 ,	0
287	C-reactive protein/albumin ratio and Glasgow prognostic score are associated with prognosis and infiltration of Foxp3+ or CD3+ lymphocytes in colorectal liver metastasis. 2022 , 22,	1

286	The Wnt pathway inhibitor RXC004 blocks tumor growth and reverses immune evasion in Wnt ligand-dependent cancer models.	1
285	Bintrafusp alfa, an anti-PD-L1:TGF- β rap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer.	2
284	Intestinal CD8 + tissue-resident memory T cells: from generation to function.	
283	Association of Tumor-infiltrating Lymphocytes (TILs) with Survival Depends on Primary Tumor Sidedness in Stage III Colon Cancers (NCCTG N0147) [Alliance]. 2022 ,	1
282	Molecular Basis of Extramural Vascular Invasion (EMVI) in Colorectal Carcinoma.	0
281	DDR1 functions as an immune negative factor in colorectal cancer by regulating tumor-infiltrating T cells through IL -18.	0
280	MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer. 2022 , 20,	2
279	Deciphering colorectal cancer immune microenvironment transcriptional landscape on single cell resolution A role for immunotherapy. 13,	0
278	Analysis of the Prognostic Significance and Immune Infiltration of the Amino Acid Metabolism-Related Genes in Colon Adenocarcinoma. 13,	0
277	Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. 12,	1
276	SPTSSA Is a Prognostic Marker for Glioblastoma Associated with Tumor-Infiltrating Immune Cells and Oxidative Stress. 2022 , 2022, 1-17	1
275	Construction of a novel signature and prediction of the immune landscape in gastric cancer based on necroptosis-related genes. 2022 , 12,	
274	Tertiary Lymphoid Structures as Mediators of Immunotherapy Response. 2022 , 14, 3748	0
273	Analysis of immune status in gastric adenocarcinoma with different infiltrating patterns and origin sites. 13,	
272	Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. 2022 , 40, 879-894.e16	0
271	Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer.	0
270	Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. 2022 , 14, 1429-1445	0
269	Anti-Colorectal Cancer Effects of Inonotus hispidus (Bull.: Fr.) P. Karst. Spore Powder through Regulation of Gut Microbiota-Mediated JAK/STAT Signaling. 2022 , 14, 3299	1

- 268 Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer. ○
- 267 Immune cellular components and signaling pathways in the tumor microenvironment. **2022**, 1
- 266 Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. 9,
- 265 HAMP as a Prognostic Biomarker for Colorectal Cancer Based on Tumor Microenvironment Analysis. 12, ○
- 264 Molecular diagnostics and biomarkers in cholangiocarcinoma. **2022**, 44, 101851 ○
- 263 Myeloid mechano-metabolic programming restricts anti-tumor immunity. ○
- 262 Reclassifying TNM stage I/II colorectal cancer into two subgroups with different overall survival, tumor microenvironment, and response to immune checkpoint blockade treatment. 13, ○
- 261 Identification of a 5-gene-based signature to predict prognosis and correlate immunomodulators for rectal cancer. **2022**, 26, 101529 ○
- 260 Artificial Intelligence-Assisted Analysis of Tumor Growth Pattern, Tumor-Infiltrating Lymphocytes, And Survival from Colorectal Cancer. ○
- 259 Immunobiology of Testicular Cancer. **2022**, ○
- 258 Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review. **2022**, 63, 486 ○
- 257 Self-supervised Antigen Detection Artificial Intelligence (SANDI). **2022**, 12-21 ○
- 256 The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers. **2022**, 20, 5065-5075 ○
- 255 Graph Neural Networks Ameliorate Potential Impacts of Imprecise Large-Scale Autonomous Immunofluorescence Labeling of Immune Cells on Whole Slide Images. ○
- 254 T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. **2022**, 14, 4246 ○
- 253 Hepatic stellate cell exosome-derived circWDR25 promotes the progression of hepatocellular carcinoma <i>via</i> the miRNA-4474-3P-ALOX-15 and EMT axes. **2022**, 16, 267-281 ○
- 252 Current Trends in Immuno-Oncology. **2022**, 20, ○
- 251 Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy. **2022**, 14, 4261 ○

250	Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. 2022 , 29, 6260-6276	0
249	Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes.	0
248	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. 2022 , 14, 4192	0
247	CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy. 2022 , 11,	0
246	Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. 2022 , 28, 1872-1882	2
245	Facts and Hopes on the Use of Artificial Intelligence for Predictive Immunotherapy Biomarkers in Cancer. OF1-OF8	0
244	Prognostic implications of immune classification using IDO1 expression in extrahepatic bile duct carcinoma. 2022 , 24,	0
243	Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. 11,	0
242	Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.	1
241	Exogenous signaling repairs defective T cell signaling inside the tumor microenvironment for better immunity. 2022 , 7,	0
240	Multi-modal digital pathology for colorectal cancer diagnosis by high-plex immunofluorescence imaging and traditional histology of the same tissue section.	0
239	Functional precision profiling reveals non-mutational rewiring of kinase signaling networks in colorectal cancer.	0
238	CD8+ T cell-associated genes MS4A1 and TNFRSF17 are prognostic markers and inhibit the progression of colon cancer. 12,	0
237	Development of a risk model based on immune genes in patients with colon adenocarcinoma.	0
236	Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model. 2022 , 22,	0
235	N6-methyladenosine in hematological malignancies: a concise review. Publish Ahead of Print,	0
234	miR-acious new avenues for cancer immunotherapy. 13,	0
233	Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. 2022 , 14, 4344	0

232	Mismatch repair proteins expression and tumor-infiltrating T-cells in colorectal cancer. 2022 , 24,	0
231	Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade. 2022 , 2022, 1-9	0
230	Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. 2022 , 14, 4346	1
229	GITR LIGATION IMPROVES ANTI-PD1-MEDIATED RESTORATION OF HUMAN MMR-PROFICIENT COLORECTAL CARCINOMA TUMOR-DERIVED T CELLS. 2022 ,	1
228	T cell-instructed inflammation drives immune checkpoint inhibitor therapy resistance.	0
227	Constructing a prognostic immune-related lncRNA model for colon cancer. 2022 , 101, e30447	0
226	Epithelial PD-L1 expression at tumor front predicts overall survival in a cohort of oral squamous cell carcinomas from Sudan.	0
225	Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. 2022 , 23, 1189-1200	1
224	Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. 2022 , 11,	4
223	The Immune Landscape of Papillary Thyroid Cancer in the Context of Autoimmune Thyroiditis. 2022 , 14, 4287	1
222	CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab. Publish Ahead of Print,	0
221	Intratumoral Niches of B Cells and Follicular Helper T Cells, and the Absence of Regulatory T Cells, Associate with Longer Survival in Early-Stage Oral Tongue Cancer Patients. 2022 , 14, 4298	0
220	Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. 12,	0
219	Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. 2022 , 3, 1026-1038	4
218	Tumor-infiltrating T cells as a risk factor for lymph node metastasis in patients with submucosal colorectal cancer.	0
217	THE DNA DAMAGE INDUCED IMMUNE RESPONSE: IMPLICATIONS FOR CANCER THERAPY. 2022 , 103409	0
216	The Role of Tumor Microenvironment in Colon Cancer. 2022 ,	0
215	Building a prognostic model based on Cytokine-related genes and exploration of colon cancer prognostic indicators.	0

214	Loss of Major Histocompatibility Complex Class I, CD8+ Tumor-infiltrating Lymphocytes, and PD-L1 Expression in Ovarian Clear Cell Carcinoma. Publish Ahead of Print,	0
213	Non-invasive measurement of tumor immune microenvironment and prediction of survival and chemotherapeutic benefits from 18F fluorodeoxyglucose PET/CT images in gastric cancer. 13,	0
212	CD45RO+TILs: cellular biomarkers for larynx squamous cell carcinoma outcome. 2022,	0
211	A Hybrid Discrete-Continuum Modelling Approach to Explore the Impact of T-Cell Infiltration on Anti-tumour Immune Response. 2022, 84,	0
210	Chromosomal Instability, Selection and Competition: Factors That Shape the Level of Karyotype Intra-Tumor Heterogeneity. 2022, 14, 4986	1
209	Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy. 13,	1
208	Effective prediction of potential ferroptosis critical genes in clinical colorectal cancer. 12,	0
207	Metagenomic meta-analysis of the gut microbiome in the different primary locations of colorectal cancer.	0
206	lncRNAs AC156455.1 and AC104532.2 as Biomarkers for Diagnosis and Prognosis in Colorectal Cancer. 2022, 2022, 1-13	0
205	Fluvoxamine prompts the antitumor immune effect via inhibiting the PD-L1 expression on mice-burdened colon tumor.	0
204	Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy. 2022, 10, e004867	1
203	Heterogeneity and Differentiation Trajectories of Infiltrating CD8+ T Cells in Lung Adenocarcinoma. 2022, 14, 5183	0
202	Clinical cancer immunotherapy: Current progress and prospects. 13,	2
201	Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. 2022, 14, 4834	0
200	IGSF6 is a novel biomarker to evaluate immune infiltration in mismatch repair-proficient colorectal cancer.	0
199	Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.	0
198	Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer. 12,	2
197	Apport de l'intelligence artificielle aux données multi-omiques dans les cancers du sein traités par chimiothérapie adjuvante. 2022, 38, 772-775	0

196	Comprehensive Characterization of the Regulatory Landscape of Adrenocortical Carcinoma: Novel Transcription Factors and Targets Associated with Prognosis. 2022 , 14, 5279	1
195	EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer. 13,	0
194	Migratory Engineering of T Cells for Cancer Therapy. 2022 , 10, 1845	1
193	Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis. 2022 , 11,	0
192	speedingCARS: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing. 2022 , 13,	2
191	A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer. 12,	0
190	Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer.	0
189	Deconvolution of bulk tumors into distinct immune cell states predicts colorectal cancer recurrence. 2022 , 25, 105392	0
188	Interdependence of sequential cytotoxic T lymphocyte and natural killer cell cytotoxicity against melanoma cells.	0
187	Loss of LXN promotes macrophage M2 polarization and PD-L2 expression contributing cancer immune-escape in mice. 2022 , 8,	0
186	The appendix orchestrates T-cell mediated immunosurveillance in colitis-associated cancer. 2022 ,	0
185	Pyroptosis predicts immunotherapy outcomes across multiple cancer types. 2022 , 245, 109163	1
184	Type I and II interferon signaling in colorectal cancer liver metastasis. 2023 , 161, 156075	1
183	T cell-inflamed gene expression profile is associated with favorable disease-specific survival in non-hypermutated microsatellite-stable colorectal cancer patients.	0
182	Combined mitoxantrone and anti-TGF β treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma. 2022 , 41,	1
181	Axin1 protects colon carcinogenesis by an immune-mediated effect. 2022 ,	0
180	Intake of Pro- and/or Prebiotics as a Promising Approach for Prevention and Treatment of Colorectal Cancer. 2200474	0
179	Prognostic Value of Immunoscore in Colorectal Carcinomas.	0

- 178 A ferroptosis-related gene signature associated with immune landscape and therapeutic response in osteosarcoma. 12, 0
- 177 Immune Cell Density Evaluation Improves the Prognostic Values of Staging and p16 in Oropharyngeal Cancer. **2022**, 14, 5560 0
- 176 MLSP: A Bioinformatics Tool for Predicting Molecular Subtypes and Prognosis in Patients with Breast Cancer. **2022**, 0
- 175 N-glycosylation regulates intrinsic IFN- γ resistance in colorectal cancer: implications for immunotherapy.. **2022**, 0
- 174 Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling. **2022**, 6, 1
- 173 Association of Tumor-Infiltrating Lymphocytes With Survival in Stages II and III Colorectal Cancer. **2022**, 0
- 172 Antibody-Based Targeted T -Cell Therapies. **2022**, 327-347 0
- 171 Development and validation of a prognostic 9-gene signature for colorectal cancer. 12, 0
- 170 Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?. **2023**, 65, 101703 0
- 169 The Janus-Faced Role of Cell-Mediated Immune Responses in Pancreatic Cancer. 62-69 0
- 168 The Anticancer Power of the Immune System [New Perspectives for Patients with Triple-Negative Breast Cancer. 54-62 0
- 167 CHARACTERIZATION OF THE IMMUNE RESPONSE THROUGH CYTOKINE PROFILING AND CORRELATIONAL ANALYSIS IN COLORECTAL MALIGNANT TUMORS. **2021**, 80, 332-341 0
- 166 Ex vivo explant model of adenoma and colorectal cancer to explore mechanisms of action and patient response to cancer prevention therapies. **2022**, 37, 227-237 0
- 165 Identification of immune subtypes and their prognosis and molecular implications in colorectal cancer. **2022**, 17, e0278114 0
- 164 Tumor immunomodulatory effects of polyphenols. 13, 0
- 163 Predictive biomarkers of colon cancer immunotherapy: Present and future. 13, 3
- 162 Deep Domain Adversarial Neural Network for the Deconvolution of Cell Type Mixtures in Tissue Proteome Profiling. 0
- 161 Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore by stage and location of colorectal cancer: an independent patient cohort study. 0

160	Prognostic Significance of Cuproptosis-Related Gene Signatures in Breast Cancer Based on Transcriptomic Data Analysis. 2022 , 14, 5771	0
159	Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumorigenesis. <i>gutjnl-2022-327608</i>	0
158	T-Cell Infiltration and Clonality May Identify Distinct Survival Groups in Colorectal Cancer: Development and Validation of a Prognostic Model Based on The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC). 2022 , 14, 5883	0
157	Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics.	0
156	Integrated analysis from multi-center studies identifies m7G-derived modification pattern and risk stratification system in skin cutaneous melanoma. 13,	0
155	Glucose to lymphocyte ratio predicts prognoses in patients with colorectal cancer.	0
154	CD8+ T-cell Density Is an Independent Predictor of Survival and Response to Adjuvant Chemotherapy in Stage III Colon Cancer. Publish Ahead of Print,	0
153	Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.	0
152	High endothelial venules proportion in tertiary lymphoid structure is a prognostic marker and correlated with anti-tumor immune microenvironment in colorectal cancer. 2023 , 55, 114-126	1
151	Role of senescent tumor cells in building a cytokine shield in the tumor microenvironment: mathematical modeling. 2023 , 86,	0
150	The intrarenal landscape of T cell receptor repertoire in clear cell renal cell cancer. 2022 , 20,	0
149	T-Cell Mediated Immunity in Merkel Cell Carcinoma. 2022 , 14, 6058	1
148	Spatial biology of cancer evolution.	4
147	Analysis of Circulating Immune Subsets in Primary Colorectal Cancer. 2022 , 14, 6105	0
146	Discrete and continuum models for the coevolutionary dynamics between CD8+ cytotoxic T lymphocytes and tumour cells.	1
145	T-cell repertoire diversity: friend or foe for protective antitumor response?. 2022 , 41,	0
144	Tumour-infiltrating lymphocytes: from prognosis to treatment selection.	3
143	The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma. 13,	0

- 142 A new prognostic model related to tumor microenvironment in colon adenocarcinoma. ○
- 141 The Colloquy between Microbiota and the Immune System in Colon Cancer: Repercussions on the Cancer Therapy. **2022**, 28, 3478-3485 ○
- 140 Fecal and Tissue Microbiota Are Associated with Tumor T-Cell Infiltration and Mesenteric Lymph Node Involvement in Colorectal Cancer. **2023**, 15, 316 ○
- 139 Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response. ○
- 138 Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response. 13, ○
- 137 General transcription factor TAF4 antagonizes epigenetic silencing by Polycomb to maintain intestine stem cell functions. ○
- 136 CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. **2023**, 56, 107-124.e5 ○
- 135 Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer. **2023**, 15, 418 ○
- 134 PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers. **2023**, 23, ○
- 133 Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer. **2023**, 12, ○
- 132 Emerging Roles of Hedgehog Signaling in Cancer Immunity. **2023**, 24, 1321 ○
- 131 Non-redundant upregulation of CD112R (PVRIG) and PD-1 on cytotoxic T-lymphocytes located in T-cell-nests of colorectal cancer. **2023**, 100089 ○
- 130 Innate immune receptor C5aR1 regulates cancer cell fate and can be targeted to improve radiotherapy in tumours with immunosuppressive microenvironments. ○
- 129 Turning Tertiary Lymphoid Structures (TLS) into Hot Spots: Values of TLS in Gastrointestinal Tumors. **2023**, 15, 367 ○
- 128 Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. 2
- 127 Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. 12, ○
- 126 Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response. **2023**, 12, 180 ○
- 125 Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer. **2022**, 13, 14872-14888 ○

- 124 PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma. **2022**, 209, 621-628 ○
- 123 Advancements in Cancer Immunotherapies. **2023**, 11, 59 ○
- 122 TILB lymphocyte expression in patient with Colorectal cancer. **2022**, 12, 62-66 ○
- 121 Immune response in patient with Colorectal cancer. **2022**, 12, 67-70 ○
- 120 Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1. **2023**, 15, 276 ○
- 119 The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies. **2023**, 12, 138 ○
- 118 CD3+/CD8+ Lymphocyte Intensity Score as Prognostic Predictor of Gastric Adenocarcinoma. ○
- 117 Lactate-related metabolic reprogramming and immune regulation in colorectal cancer. 13, ○
- 116 The Expression of ARM CX1 in Gastric Cancer Contributes to Prognosis and Influences Chemotherapy. **2023**, 2023, 1-12 ○
- 115 Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. **2023**, 22, 153303382211505 ○
- 114 Myeloperoxidase promotes a tumorigenic microenvironment in non-small cell lung cancer. ○
- 113 Tumor immunology. **2023**, 245-452 ○
- 112 Clinical Plasma Cells-related Genes to Aid Therapy in Colon Cancer. ○
- 111 ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation. **2023**, 13, ○
- 110 A Brief Overview of Cancer Vaccines. **2023**, 29, 34-37 ○
- 109 A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. 12, ○
- 108 Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma. 14, ○
- 107 The Controversial Role of Intestinal Mast Cells in Colon Cancer. **2023**, 12, 459 ○

- 106 Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy. **2023**, 15, 452 ○
- 105 Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. **2023**, 15, 863 ○
- 104 Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer. 13, ○
- 103 Role of Immune Cells in the Tumor Microenvironment. **2023**, ○
- 102 Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. **2023**, 15, 1433 ○
- 101 Tumor-infiltrating T cells as a risk factor for lymph node metastasis in patients with submucosal colorectal cancer. **2023**, 13, ○
- 100 IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients in a cohort study. **2023**, 109, 323-332 ○
- 99 Identification of a novel Immune-Related prognostic model for patients with colorectal cancer based on 3 subtypes. **2023**, 228, 152352 ○
- 98 Transcriptomes of the tumor-adjacent normal tissues are more informative than tumors in predicting recurrence in colorectal cancer patients. **2023**, 21, ○
- 97 Application of radiomics in lung immuno-oncology. ○
- 96 Comprehensive analysis of novel cancer prediction genes and tumor microenvironment infiltration in colon cancer. ○
- 95 Deciphering the Tumour Immune Microenvironment Cell by Cell. **2023**, 100383 ○
- 94 Prognostic value of tumor-associated regulatory T-cells as a biomarker in non-small cell lung cancer: a systematic review and meta-analysis. ○
- 93 Anti-tumor effects of anti-programmed cell death-1 antibody treatment are attenuated in streptozotocin-induced diabetic mice. **2023**, 13, ○
- 92 The involvement of Th1 cell differentiation in the anti-tumor effect of purified polysaccharide from *Sanguangporus vaninii* in colorectal cancer via multi-omics analysis. **2023**, 237, 123927 ○
- 91 A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies. **2023**, 61, 102644 ○
- 90 The evolving landscape of PCSK9 inhibition in cancer. **2023**, 949, 175721 ○
- 89 Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. **2023**, 161, 114567 ○

- 88 On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer. **2023**, 7, 291-311 ○
- 87 NIR responsive nanoenzymes via photothermal ablation and hypoxia reversal to potentiate the STING-dependent innate antitumor immunity. **2023**, 19, 100566 ○
- 86 An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. **2023**, 88, 104452 ○
- 85 T cells and their clinical application in colon cancer. 14, 1
- 84 CD8+ CD226^{high} T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery. **2023**, 20, 365-378 ○
- 83 Distinct role of tumor-infiltrating lymphocytes between synchronous and metachronous colorectal cancer. **2023**, 408, ○
- 82 Vaccination-Based Immunoprevention of Colorectal Tumors. **2023**, 57, 246-252 1
- 81 Characterization of the microenvironment in different immune-metabolism subtypes of cervical cancer with prognostic significance. 14, ○
- 80 Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape. **2023**, 15, 1022 ○
- 79 Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA). **2023**, 15, 994 ○
- 78 How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. ○
- 77 Characterization of the immune cell landscape in CRC: Clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. 13, ○
- 76 The M2 macrophages infiltration of sebaceous tumors is linked to the aggressiveness of tumors but not to the mismatch repair pathway. ○
- 75 EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. **2023**, 10, ○
- 74 Cold Colorectal cancer faces a bottleneck in immunotherapy. 15, 240-250 ○
- 73 Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study. 15, 303-317 ○
- 72 Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports. **2023**, 32, 187-200 ○
- 71 IGSF6 is a novel biomarker to evaluate immune infiltration in mismatch repair-proficient colorectal cancer. ○

- 70 OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. **2023**, 4, 100939 ○
- 69 The Prognostic Impact of Gender, Therapeutic Strategies, Molecular Background, and Tumor-Infiltrating Lymphocytes in Glioblastoma: A Still Unsolved Jigsaw. **2023**, 14, 501 ○
- 68 Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. **2023**, 22, ○
- 67 The effect of perioperative blood transfusion on survival after renal cell carcinoma nephrectomy: A systematic review and meta-analysis. 13, ○
- 66 TIPE2 acts as a tumor suppressor and correlates with tumor microenvironment immunity in epithelial ovarian cancer. ○
- 65 The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1+ CD8+ T cells in chronic viral infection. **2023**, 56, 813-828.e10 ○
- 64 Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer. **2023**, 9, ○
- 63 High endothelial venules in cancer: Regulation, function, and therapeutic implication. **2023**, 41, 527-545 ○
- 62 Dissecting the inflammatory tumor microenvironment of esophageal adenocarcinoma: mast cells and natural killer cells are favorable prognostic factors and associated with less extensive disease. ○
- 61 Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8+ T cells with enhanced tumor homing to improve cell therapy. **2023**, 42, 112175 ○
- 60 CD169 + sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer. ○
- 59 Immune Microenvironment in Sporadic Early-Onset versus Average-Onset Colorectal Cancer. **2023**, 15, 1457 ○
- 58 Prognostic Significance of Tumor-Infiltrating Lymphocytes Determined Using LinkNet on Colorectal Cancer Pathology Images. **2023**, ○
- 57 Myeloid-Derived Suppressor Cell Dynamics Control Outcomes in the Metastatic Niche. OF1-OF15 ○
- 56 β -adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN- γ -dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma. ○
- 55 Immune escape of colorectal tumours via local LRH -1/Cyp11b1-mediated synthesis of immunosuppressive glucocorticoids. ○
- 54 CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. **2023**, 13, 465 ○
- 53 N6-methyladenosine related gene expression signatures for predicting the overall survival and immune responses of patients with colorectal cancer. 14, ○

- 52 Phenotypic subtypes predict outcomes in colorectal cancer. **2023**, 62, 245-252 ○
- 51 Integrated analysis identifies oxidative stress-related lncRNAs associated with progression and prognosis in colorectal cancer. **2023**, 24, ○
- 50 Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?. 14, ○
- 49 A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection: A multicenter retrospective study. 1 ○
- 48 Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. 14, ○
- 47 Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME). 14, ○
- 46 DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy. **2023**, 15, 1619 ○
- 45 Nomogram Based on Preoperative Fibrinogen and Systemic Immune-Inflammation Index Predicting Recurrence and Prognosis of Patients with Borrmann Type III Advanced Gastric Cancer. Volume 16, 1059-1075 ○
- 44 The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. **2023**, 41, 374-403 ○
- 43 First passage time analysis of spatial mutation patterns reveals sub-clonal evolutionary dynamics in colorectal cancer. **2023**, 19, e1010952 ○
- 42 Molecular cartography uncovers evolutionary and microenvironmental dynamics in sporadic colorectal tumors. ○
- 41 The current understanding of the immune landscape relative to radiotherapy across tumor types. 14, ○
- 40 A common cancer at an uncommon age. **2023**, 379, 1088-1090 ○
- 39 NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer. **2023**, 15, 1792 ○
- 38 The Potential Revolution of Cancer Treatment with CRISPR Technology. **2023**, 15, 1813 ○
- 37 An integrated analysis of Dynamin 1 Like: A new potential prognostic indicator in hepatocellular carcinoma. ○
- 36 Definition of a Novel Immunogenic Cell Death-Relevant Gene Signature Associated with Immune Landscape in Gastric Cancer. ○
- 35 S3-CIMA: Supervised spatial single-cell image analysis for the identification of disease-associated cell type compositions in tissue. ○

- 34 Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies. 13, ○
- 33 Towards a consensus definition of immune exclusion in cancer. 14, ○
- 32 Weakly supervised deep learning to predict recurrence in low-grade endometrial cancer from multiplexed immunofluorescence images. **2023**, 6, ○
- 31 Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma. 10, ○
- 30 T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma. **2023**, 14, 785 ○
- 29 The role of dendritic cells in radiation-induced immune responses. **2023**, ○
- 28 Immune Modulations of the Tumor Microenvironment in Response to Phototherapy. ○
- 27 Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. **2023**, 7, 281-297 ○
- 26 Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile. ○
- 25 Combining the guidelines and multiphoton imaging methods to improve the prognostic value of tumor-infiltrating lymphocytes in breast cancer. ○
- 24 CD4+ T cells in cancer. **2023**, 4, 317-329 1
- 23 Mesenchymal stem cells can prevent or promote the progression of colon cancer based on their timing of administration. **2023**, 21, ○
- 22 An immunometabolism subtyping system identifies S100A9+ macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis. **2023**, 4, 100987 ○
- 21 Das Immunsystem und Krebs. **2023**, 29-50 ○
- 20 Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma. 14, ○
- 19 Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. ○
- 18 Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions. 14, ○
- 17 Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. ○

- 16 GEGVIC: A workflow to analyze Gene Expression, Genetic Variations and Immune cell Composition of tumor samples using Next Generation Sequencing data. ○
- 15 Tumor-Infiltrating CD45RO+ Memory Cells Are Associated with Favorable Prognosis in Oral Squamous Cell Carcinoma Patients. **2023**, 15, 2221 ○
- 14 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 13 TGFβ and the Tumor Microenvironment in Colorectal Cancer. **2023**, 12, 1139 ○
- 12 Novel strategies for cancer immunotherapy: counter-immunoediting therapy. **2023**, 16, ○
- 11 Sequential chromogenic immunohistochemistry: spatial analysis of lymph nodes identifies contact interactions between plasmacytoid dendritic cells and plasmablasts. ○
- 10 Association of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma. **2023**, 15, 2346 ○
- 9 Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review. 13, ○
- 8 Information about immune cell proportions and tumor stage improves the prediction of recurrence in patients with colorectal cancer. **2023**, 100736 ○
- 7 Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer. **2023**, 23, ○
- 6 Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. **2023**, 11, e006633 ○
- 5 Late-stage MC38 tumours recapitulate features of human colorectal cancer ¶ implications for appropriate timepoint selection in preclinical studies. 14, ○
- 4 China special issue on gastrointestinal tumor: Regulatory-immunoscore¶ a novel indicator to guide precision adjuvant chemotherapy in colorectal cancer. ○
- 3 The ¶ Great Debate¶ at Immunotherapy Bridge 2022, Naples, November 30thDecember 1st, 2022. **2023**, 21, ○
- 2 Arteriosclerosis Decreases Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression on Liver Natural Killer Cells in Living Donor Liver Transplantation. **2023**, ○
- 1 The Prognostic Role of the Immune Microenvironment in Sinonasal Intestinal-Type Adenocarcinoma: A Computer-Assisted Image Analysis of CD3+ and CD8+ Tumor-Infiltrating Lymphocytes. **2023**, 13, 726 ○